2-SUBSTITUTED QUINOLINE DIOIC ACIDS

Abstract: Compounds having the formula: are antagonists of leukotrienes and inhibitors of their biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.

Description: BACKGROUND OF THE INVENTION This invention is directed to compounds which act as antagonists of the leukotrienes and inhibitors of their biosynthesis. The leukotrienes and their biological activities, especially their roles in various disease states and conditions have been described. For example, see EP l40,684 (May 8, l985), which is incorporated herein by reference. Several classes of compounds exhibit ability to antagonize the action of leukotrienes in mammals, especially humans. See for example: United Kingdom Patent Specification Nos. 2,058,785 and 2,094,30l; and European Patent Application Nos. 56,l72, 6l,800 and 68,739. EP ll0,405 (June l3, l984) describes anti-­ inflammatory and antiallergic substituted benzenes which are disclosed to be leukotriene inhibitors, i.e., inhibitors of the 5-lipoxygenase pathway. SUMMARY OF THE INVENTION The present invention relates to compounds having activity as leukotriene and SRS-A antagonists or inhibitors, to methods for their preparation, to intermediates useful in their preparation and to methods and pharmaceutical formulations for using these compounds in mammals (especially humans). Because of their activity as leukotriene antagonists or inhibitors, the compounds of the present invention are useful as anti-asthmatic, anti-allergic, and anti-inflammatory agents and are useful in treating allergic rhinitis and chronic bronchitis and for amelioration of skin diseases like psoriasis and atopic eczema. These compounds are also useful to antagonize or inhibit the pathologic actions of leukotrienes on the cardiovascular and vascular systems for example, actions such as result in angina. The compounds of the present invention are useful in the treatment of inflammatory and allergic diseases of the eye, including allergic conjunctivitis. The compounds are also useful as cytoprotective agents. Thus, the compounds of the present invention may also be used to treat or prevent mammalian (especially, human) disease states such as erosive gastritis; erosive esophagitis; inflammatory bowel disease; ethanol-induced hemorrhagic erosions; hepatic ischemic; noxious agent induced damage or necrosis of hepatic, pancreatic, renal, or myocardial tissue; liver parenchymal damage caused by hepatoxic agents such as CCl₄ and D-galactosamine; ischemic renal failure; disease-induced hepatic damage; bile salt induced pancreatic or gastric damage; trauma- or stress-induced cell damage; and glycerol-induced renal failure. DETAILED DESCRIPTION The compounds of this invention are best realized by Formula I: wherein: R¹ is H, halogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, -CF₃, -OR², -SR², -S(O)R², -S(O)₂R², -NR²R², -CHO, -COOR², -(C=O)R², -C(OH)R²R², -CN, -NO₂, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, or substituted or unsubstituted phenethyl; R² is H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, -CF₃, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, or substituted or unsubstituted phenethyl; R³ is H, halogen, -NO₂, -CN, -OR², -SR², NR²R², or C₁-C₈ alkyl; CR²R³ may be the radical of a naturally occuring amino acid; R⁴ is H, halogen, -NO₂, -CN, -OR², -SR², NR²R², C₁-C₈ alkyl, or -(C=O)R²; R⁶ is H or C₁-C₄ alkyl; R⁷ is A) a monocyclic or bicyclic heterocyclic radical containing from 3 to l2 nuclear carbon atoms and l or 2 nuclear hetero­ atoms selected from N, S or O and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or B) the radical W-R⁸; R⁸ contains up to 2l carbon atoms and is (l) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more than l heteroatom in the ring; R⁹ is -OR¹⁰, -SR¹⁰, or NR¹⁰R¹⁰; R¹⁰ is H, C₁-C₆ alkyl, -(C=O)R¹¹, unsubstituted phenyl, unsubstituted benzyl, or two R¹⁰ groups joined to the same N may form a ring of 5 or 6 members containing up to two heteratoms chosen from O, S or N; R¹¹ is H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, -CF₃, or unsubstituted phenyl, benzyl, or phenethyl; R¹² is R² or halogen; m and m′ are independently 0-8; n and n′ are independently 0 or l; p and p′ are independently 0-8; m + n + p is l-l0; m′ + n′ + p′ is l-l0; s is 0-3; Q¹ and Q² are independently -COOR², tetrazole, -COOR⁵, -CONHS(O)₂R¹¹, -CN, -CONR¹⁰R¹⁰, -CHO, -CH₂OH, -COCH₂OH, -NHS(O)₂R¹¹; or if Q¹ or Q² is COOH and R³ is -OH, -SH, or -NHR² then Q¹ or Q² and R³ and the carbons through which they are attached may form a heterocyclic ring with loss of water; W is O, S, or NH; X¹ is O, S, -S(O)-, -S(O)₂-, -NR², or -CR²R²-; X² and X³ are independently O, S, S(O), or S(O)₂; Z¹ and Z² are independently -CONR²-; and the pharmaceutically acceptable salts thereof. Alkyl, alkenyl, and alkynyl are intended to include linear, branched, and cyclic structures. Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl sec- and tert-butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl and the like. Alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, l-propenyl, 2-butenyl, 2-methyl-2-butenyl, norbornenyl, and the like. Substituted phenyl, benzyl, and phenethyl include l or 2 substituents on the benzene ring selected from C₁-C₆ alkyl, R⁹, NO₂, SCF₃, halogen, -COR⁶, -COR⁹, CN, and CF₃. Halogen includes F, Cl, Br and I. The prodrug esters of Q (i.e., when Q = -COOR⁵) are intended to include the esters such as are described by Saari et al ., J. Med Chem., 2l , No. 8, 746-753 (l978). When Q and R³ and the carbons through which they are attached form a ring, the rings thus formed include lactones, lactams, and thiolactones. It is intended that the definitions of any substituent (e.g., R¹, R², m, Q, X, etc.) in a particular molecule be independent of its definitions elsewhere in the molecule. Thus, -NR²R² represents -NHH, -NHCH₃, NHC₆H₅, etc. The heterocycles formed when two R¹⁰ groups join through N include pyrrolidine, piperidine, morpholine, thiamorpholine, piperazine, and n-methylpiperazine. The naturally occuring amino acids, the radicals of which may be CR²R³, include alanine, asparagine, aspartic acid, arginine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenyl­ alanine, proline, serine, threonine, tryptophan, tyrosine and valine. Examples of Z-CR²R³-Q containing a naturally occurring amino acid radical include: Some of the compounds described herein contain one or more centers of asymmetry and may thus give rise to diastereoisomers and optical isomers. The present invention is meant to comprehend such possible diastereoisomers as well as their racemic and resolved, optically active forms. Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers. Preferred compounds of Formula I are best represented by Formula Ia: wherein: Y is -CR²=CR²-, -CC-, CRO, or -CRS-; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. More-preferred compounds of Formula I are best represented by Formula Ib: wherein: R¹ is H, halogen, C₁-C₃ alkyl, -CF₃, or SCF₃; R² is H, C₁-C₃ alkyl, C₂-C₃ alkenyl, or -CF₃; X² and X³ are independently O or S; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. Other more-preferred compounds of Formula I are best represented by Formula Ic: wherein: R¹ is H, halogen, C₁-C₃ alkyl, -CF₃, or SCF₃; R² is H, C₁-C₃ alkyl, C₂-C₃ alkenyl, or -CF₃; X² and X³ are independently O or S; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. Other more-preferred compounds within the scope of this invention are best represented by Formula Id: wherein: R¹ is H, halogen, C₁-C₃ alkyl, CF₃ or SCF₃; R² is H, C₁-C₃ alkyl, C₂-C₃ alkenyl, or CF₃; X² and X³ are independently O or S; Y is -CRO- or -CRS-; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. A preferred embodiment of compounds of formulae Ib, Ic, or Id is that wherein Q¹ or Q² is COOR², tetrazole, COOR⁵, CONR¹⁰R¹⁰ or COCH₂OH, with the remaining substituent being defined as for Ib, Ic or Id, respectively. The compounds of Formula I are active as antagonists of SRS-A and especially of leukotriene D₄. These compounds also have modest inhibitory activity on leukotriene biosynthesis but are primarily of therapeutic interest as antagonists. The activity of the compounds of Formula I can be detected and evaluated by methods known in the art. See for example, Kadin , U.S. Patent No. 4,296,l29. The ability of the compounds of Formula I to antagonize the effects of the leukotrienes and to inhibit the leukotrienes makes them useful for inhibiting the symptoms induced by the leukotrienes in a human subject. The compounds are valuable therefore in the prevention and treatment of such disease states in which the leukotrienes are the causative factor, e.g. skin disorders, allergic rhinitis, and obstructive airway diseases. The compounds are particularly valuable in the prevention and treatment of allergic bronchial asthma. They are also effective in the treatment of inflammatory diseases of the eye. It will be understood that in this paragraph and in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to include the pharmaceutically acceptable salts and lactone, lactam or thiolactone forms. The cytoprotective activity of a compound may be observed in both animals and man by noting the increased resistance of the gastrointestinal mucosa to the noxious effects of strong irritants, for example, the ulcerogenic effects of aspirin or indomethacin. In addition to lessening the effect of non-steroidal anti-inflammatory drugs on the gastrointestinal tract, animal studies show that cytoprotective compounds will prevent gastric lesions induced by oral administration of strong acids, strong bases, ethanol, hypertonic saline solutions and the like. Two assays can be used to measure cytoprotective ability. These assays are; (A) an ethanol-induced lesion assay and (B) an indomethacin-induced ulcer assay and are described in EP l40,684. The magnitude of a prophylactic or thera­ peutic dose of a compound of Formula I will, of course, vary with the nature of the severity of the condition to be treated and with the particular compound of Formula I and its route of administration. It will also vary according to the age, weight and response of the individual patient. In general, the daily dose range for anti-asthmatic, anti-allergic or anti-inflammatory use and generally, uses other than cytoprotection, lie within the range of from about 0.00l mg to about l00 mg per kg body weight of a mammal, preferably 0.0l mg to about l0 mg per kg, and most preferably 0.l to l mg per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases. The exact amount of a compound of the Formula I to be used as a cytoprotective agent will depend on, inter alia , whether it is being administered to heal damaged cells or to avoid future damage, on the nature of the damaged cells (e.g., gastrointestinal ulcerations vs. nephrotic necrosis), and on the nature of the causative agent. An example of the use of a compound of the Formula I in avoiding future damage would be co-administration of a compound of the Formula I with a non-steroidal anti-inflammatory drug that might otherwise cause such damage (for example, indomethacin). For such use, the compound of Formula I is administered from 30 minutes prior up to 30 minutes after administra­ tion of the NSAID. Preferably it is administered prior to or simultaneously with the NSAID, (for example, in a combination dosage form). The effective daily dosage level for compounds of Formula I inducing cytoprotection in mammals, especially humans, will generally range from about 0.l mg/kg to about l00 mg/kg, preferably from about l mg/kg to about l00 mg/kg. The dosage may be administered in single or divided individual doses. Any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a leukotriene antagonist. For example, oral, rectal, topical, parenteral, ocular, nasal, buccal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids. Salts derived from inorganic bases include sodium, potassium, lithium, ammonium, calcium, magnesium, ferrous, zinc, copper, manganous, aluminum, ferric, manganic salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropyl­ amine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzene­ sulfonic, benzoic, camphorsulfonic, citric, ethane­ sulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic and the like. Particularly preferred are hydrobromic, hydrochloric, phosphoric and sulfuric acids. The compositions include compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy. For use where a composition for intravenous administration is employed, a suitable dosage range for anti-asthmatic, anti-inflammatory or anti-­ allergic use is from about 0.00l mg to about l0 mg (preferably from about 0.0l mg to about l mg) of a compound of Formula I per kg of body weight per day and for cytoprotective use from about 0.l mg to about l00 mg (preferably from about l mg to about l00 mg and more preferably from about l mg to about l0 mg) of a compound of Formula I per kg of body weight per day. In the case where an oral composition is employed, a suitable dosage range for anti-­ asthmatic, anti-inflammatory or anti-allergic use is, e.g. from about 0.0l mg to about l00 mg of a compound of Formula I per kg of body weight per day, preferably from about 0.l mg to about l0 mg per kg and for cyto­ protective use from about 0.l mg to about l00 mg (preferably from about l mg to about l00 mg and more preferably from about l0 mg to about l00 mg) of a compound of Formula I per kg of body weight per day. For administration by inhalation, the compounds of the present invention are conveniently delivered in the form of an aerosol spray presenta­ tion from pressurized packs or a nebuliser, or as a powder which may be formulated as a cartridge from which the powder composition may be inhaled with the aid of a suitable device. The preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution in fluorocarbon propellants. Suitable topical formulations of Compound I include transdermal devices, aerosols, creams, ointments, lotions, dusting powders, and the like. For the treatment of diseases of the eye, ophthalmic preparations for ocular administration comprising 0.00l-l% by weight solutions or suspensions of the compounds of Formula I in an acceptable ophthalmic formulation may be used. In practical use, the compounds of Formula I can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets, with the solid oral preparations being preferred over the liquid preparations. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. In addition to the common dosage forms set out above, the compounds of Formula I may also be administered by controlled release means and/or delivery devices such as those described in U.S. Patent Nos. 3,845,770; 3,9l6,899; 3,536,809; 3,598,l23; 3,630,200 and 4,008,7l9, the disclosures of which are hereby incorporated herein by reference. Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier which consti­ tutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Desirably, each tablet contains from about 2.5 mg to about 500 mg of the active ingredient and each cachet or capsule contains from about 2.5 to about 500 mg of the active ingredient. The following are examples of representative pharmaceutical dosage forms for the compounds of Formula I: In addition to the compounds of Formula I, the pharmaceutical compositions of the present invention can also contain other active ingredients, such as cyclooxygenase inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), peripheral analgesic agents such as zomepirac, diflunisal and the like. The weight ratio of the compound of the Formula I to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the Formula I is combined with an NSAID the weight ratio of the compound of the Formula I to the NSAID will generally range from about l000:l to about l:l000. Combinations of a compound of the Formula I and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used. NSAIDs can be characterized into five groups: (l) the propionic acid derivatives; (2) the acetic acid derivatives; (3) the fenamic acid derivatives; (4) the biphenylcarboxylic acid derivatives; and (5) the oxicams or a pharmaceutically acceptable salt thereof. NSAIDs which are within the scope of this invention are those disclosed in EP l40,684. Pharmaceutical compositions comprising the Formula I compounds may also contain inhibitors of the biosynthesis of the leukotrienes such as are disclosed in EP l38,48l (April 24, l985), EP ll5,394 (August 8, l984), EP l36,893 (April l0, l985), and EP l40,709 (May 5, l985), which are hereby incorporated herein by reference. The compounds of the Formula I may also be used in combination with leukotriene antagonists such as those disclosed in EP l06,565 (April 25, l984) and EP l04,885 (April 4, l984) which are hereby incorporated herein by reference and others known in the art such as those disclosed in European Patent Application Nos. 56,l72 (July 2l, l982) and 6l,800 (October 6, l982); and in U.K. Patent Specification No. 2,058,785, which are hereby incorporated herein by reference. Pharmaceutical compositions comprising the Formula I compounds may also contain as the second active ingredient prostaglandin antagonists such as those disclosed in European Patent Applications ll,067 (May 28, l980), l66,59l (January 2, l986) or thromboxane antagonists such as those disclosed in U.S. 4,237,l60. They may also contain histidine decarboxylase inhibitors such as α-fluoromethyl­ histidine, described in U.S. 4,325,96l. The compounds of the Formula I may also be advantageously combined with an H₁ or H₂-receptor antagonist, such as for instance benadryl, dramamine, histadyl, phenergan, terfenadine, acetamazole, cimetidine, ranitidine, famotidine, aminothiadiazoles disclosed in EP 40,696 (December 2, l98l) and like compounds, such as those disclosed in U.S. Patent Nos. 4,283,408; 4,362,736; and 4,394,508. The pharmaceutical compositions may also contain a K⁺/H⁺ ATPase inhibitor such as omeprazole, disclosed in U.S. Pat. 4,255,43l, and the like. Another useful pharmaceutical composition comprises the Formula I compounds in combination with serotonin antagonists such as methysergide, the serotonin antagonists disclosed in Nature , vol. 3l6, pages l26-l3l, l985, and the like. Each of the references referred to in this paragraph is hereby incorporated herein by reference. Compounds of the present invention can be prepared according to the following methods. In these schemes, the 2-substituted quinoline radical is represented by "2SQ-". METHOD A : Referring to Method A, an aniline derivative of Formula II is reacted by heating with a croton­ aldehyde and a strong mineral acid such as aqueous hydrochloric acid to provide the substituted quinaldine derivative of structure III. When II is unsymmetrical two regioisomers of III may be obtained. The products are purified by precipitation of the zinc chloride adducts or by standard chromatographic techniques. Quinaldine III is reacted with isophthalaldehyde derivative IV by heating with a dehydrating agent, most preferably by heating with acetic anhydride, to provide the 2-styryl quinoline derivative of structure V. Reaction of the styrylaldehyde V with an alkanoic acid or tetrazole terminally substituted with a thiol or hydroxy group in an inert solvent such as benzene in the presence of a suitable catalyst such as BF₃.OEt affords the stryrylquinoline derivative VI, which is a representative of structure I. METHOD B : Alternatively an isophthalaldehyde deriva­ tive of structure IV is reacted with an alkanoic acid or tetrazole terminally substituted with a thiol or hydroxy group in an inert solvent such as benzene in the presence of a suitable catalyst such as BF₃.OEt or trimethyl silylchloride to afford the acetal derivative VII. Quinoline derivative III is condensed with aldehyde VII by heating with a dehydrating agent, preferably acetic anhydride, to provide the 2-styrylquinoline ketal of structure VI, which is a representative of structure I. METHOD C : Aldehyde VIII is reacted with an alkanoic acid or tetrazole terminally substituted with a thiol or hydroxy group in an inert solvent such as benzene in the presence of a suitable catalyst such as BF₃.OEt to afford the acetal derivative IX. The acetal derivative IX is then reacted with a quinaldine derivative of general structure X, in which Z is a leaving group such as Br or methanesulfonate, in the presence of a suitable base such as NaOH, NaH, K₂CO₃ in an inert solvent such as THF, dioxane, DMF, etc., with warming if necessary to provide adducts XI. The required quinaldine X is prepared by standard methods from quinaldine derivatives of formula III. METHOD D : An alternative preparation of compound VI is to convert a quinaldine derivative X (Z = halogen) to X (Z = Ph3P⁺) to form a Wittig reagent, which may be reacted with a base such as butyl lithium and the aldehyde VII to produce VI. METHOD E : An alternate preparation of compounds of type XIV, a subtype of VII, is as follows. A dialdehyde of structure IV is reacted with one equivalent of the appropriate thiol XII and one equivalent of thiol acid, RC(O)SH, in a solvent such as benzene with an acid such as p-toluenesulfonic acid to give the compound of general structure XIII which is purified by chromatography. The purified XIII is reacted in methanol or ethanol preferably at low temperature but also up to room temperature with a base such as NaOMe (or NaOH or Na₂CO₃) followed by a Michael aceptor olefin to give asymmetric thioacetal XIV. In Method E, Q³ is -COOR², -COOR⁵, -CN, -CONR¹⁰R¹⁰ or CHO and R is C₁-C₁₂ alkyl, phenyl or substituted phenyl, or is the radical from an optically active carboxylic acid such as α-methoxy phenylacetic acid, abietic acid, camphoric acid, cis-2-benzamidocyclohexane carboxylic acid, diacetyl tartaric anhydride, α-methoxy-α-trifluoromethyl­ phenylacetic acid, menthyloxyacetic acid, 2-methyl­ butyric acid, 2-phenylbutyric acid, 2-phenylpropionic acid or pyrogutamic acid. In cases where VI or XI contains an ester group, they may be hydrolyzed in a mixture of a polar solvent such as THF and a strong base such as aqueous sodium hydroxide to provide the respective salts, acidification of which provides the corresponding acids. These salts and acids are also represent­ atives of structure I. The invention is further defined by reference to the following examples, which are intended to be illustrative and not limiting. All temperatures are in degrees Celsius. In Table l are shown some representative Formula I compounds. EXAMPLE l 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-4,6-­ DITHIANONANEDIOIC ACID Step l : Preparation of dimethyl 5-(3-formylphenyl)-­ 4,6-dithianonanedioate To a solution of isophthalaldehyde (5.4 g) in CHCl₃ (50 ml) and methyl 3-mercaptopropanoate (9.2 ml) was added dropwise trimethylsilylchloride (6.5 ml). The reaction mixture was stirred l hour at room temperature, quenched with aqueous NH₄OAc (25%), and extracted with ethylacetate. Flash chromatography of the residue using l:l ethylacetate hexane afforded the title compound. p.m.r. (CD₃COCD₃) δ : 2.6-3.0 (m, 8H); 3.60 (s, 6H); 5.5 (s, lH); 7.6 (t, lH); 7.8-8.0 (m, 2H); 8.05 (m, lH); l0.05 p.p.m. (s, lH). Step 2 : Preparation of dimethyl 5-(3-(2-(7-chloro­ quinolin-2-yl)ethenyl)phenyl)-4,6-dithiano­ nanedioate A solution of aldehyde (Step l) (5.2 g) and 7-chloroquinaldine were heated in 45 ml acetic anhydride for 48 hours. The reaction mixture was evaporated. Flash chromatography of the residue using 5% ethylacetate in hexane afforded the title compound. p.m.r. (CD₃COCD₃) δ : 2.6-3.0 (m, 8H); 3.65 (s, 6H); 5.32 (s, lH); 7.4-7.6 (m, 4H); 7.65 (m, lH); 7.85-8.05 (m, 5H); 8.35 p.p.m. (d, lH). Step 3 : To a solution of dimethyl ester (Step 2) (l.7 g) in l,2-dimethoxyethane (60 ml) was added lithium hydroxide (l0 ml of 2N). The reaction mixture was stirred overnight at room temperature. H₂O (l00 ml) was added and the l,2-dimethoxyethane was removed under vacuo. The solution was extracted with ethylacetate (300 ml). The aqueous phase was acidified to pH 3, extracted with ethylacetate (200 ml), dried and evaporated. Flash chromatography of the residue using 5% EtOH in CH₂Cl₂ with l% of acetic acid afforded the title compound. p.m.r. (CD₃COCD₃ + 3 drops CD₃SOCD₃) δ: 2.6-3.0 (m, 8H); 5.35 (s, lH); 7.4-7.55 (m, 4H), 7.6-7.7 (m, lH); 7.8-8.05 (m, 5H) and 8.35 p.p.m. (d, lH). EXAMPLE 2 DISODIUM 5-(3-(2-(7-BROMOQUINOLIN-2-YL)ETHENYL)­ PHENYL)-4,6-DITHIANONANEDIOIC ACID Step l : Preparation of dimethyl-5-(3-(2-(7-bromo­ quinolin-2-yl)ethenyl)phenyl)-4,6-­ dithianonanedioic acid Using the procedure of Example l (Step 2), but substituting 7-bromoquinaldine for 7-chloro­ quinaldine was obtained the title compound. p.m.r. (CD₃COCD₃ δ : 2.6-3.0 (m, 8H); 3.65 (s, 6H); 5.35 (s, lH); 7.4-7.55 (m, 3H); 7.6-7.7 (m, 2H); 7.8-7.95 (m, 4H); 8.2 (d, lH); 8.3 p.p.m. (d, lH). Step 2 : To a solution of dimethyl ester (Step l) (l g) in THF (l0 ml) and EtOH (l0 ml) at room temperature was added 3 ml of 2N NaOH. The reaction mixture was stirred 2 days at room temperature. The solution was evaporated. Purification of the residue by reverse phase HPLC (Waters C₁₈ µ-bondapak column) using H₂O/MeOH (35:65) buffered at pH 5.5 afforded the title compound contaminated with salts. The residue was dissolved in aqueous NaOH and applied on an XAD-8 column. The column was first eluted with H₂O. Elution with ethanol afforded the title compound. p.m.r. (CD₃SOCD₃) δ : 2.3-2.9 (m, 8H); 5.30 (s, lH); 7.3-7.5 (m, 2H); 7.6-8.0 (m, 7H); 8.l5 (d, lH); 8.35 p.p.m. (d, lH). EXAMPLE 3 5-(3-((7-CHLOROQUINOLIN-2-YL-METHYL)OXY)PHENYL)-­ 4,6-DITHIANONANEDIOIC ACID Step l : Preparation of dimethyl 5-(3-hydroxyphenyl)-­ 4,6-dithianonanedioate To a solution of 3-hydroxybenzaldehyde (3.6 g) and methyl 3-mercaptopropanoate (8.0 ml) in benzene (l00 ml) was added boron trifluoride etherate (l.0 ml). The reaction mixture was stirred overnight at room temperature, quenched with aqueous NH₄OAc, extracted with ether, dried and evaporated. Flash chromatography of the residue using 40% ethyl acetate in hexane afforded the title compound. p.m.r. (CDCl₃) δ : 2.5-3.0 (m, 8H); 3.7 (s, 6H); 4.8 (s, lH); 6.3 (bs, lH); 6.8-7.2 p.p.m. (m, 4H). Step 2 : Preparation of 2-bromomethyl-7-chloro­ quinoline A stirred suspension of N-bromosuccinimide (9.0 g), 7-chloroquinaldine (9.0 g), dibenzoyl­ peroxide (.5 g) in CCl₄ (200 ml) at 90⁰ was illuminated with a 225W sunlamp for 6 hours. The suspension was cooled and passed through a plug of silica gel. The plug of silica gel was washed with 30% ether in hexane and the filtrate was evaporated. Flash chromatography of the residue using 30% ether in hexane afforded the title compound. p.m.r. (CDCl₃) δ : 4.3 (s, 2H); 7.0-8.0 p.p.m. (m, 5H). Step 3 : Preparation of dimethyl 5-(3-((7-chloro­ quinolin-2-yl-methyl)oxy)phenyl)-4,6-­ dithianonanedioate A mixture of 2-bromomethyl-7-chloro­ quinoline (2.5 g) (Step 2), phenol (Step l) (3.4 g) and K₂CO₃ (3 g) was heated at reflux for 4 hours in methyl ethyl ketone (l00 ml). The reaction mixture was cooled and ether (l00 ml) was added. The suspension was filtered and evaporated. Flash chromatography of the residue using 30% ethyl acetate in hexane afforded the title compound. p.m.r. (CD₃COCD₃) δ : 2.6-3.0 (m, 8H); 3.60 (s, 6H); 5.2 (s, lH); 5.35 (s, 2H); 7.0 (m, lH); 7.l (lH); 7.2-7.3 (m, 2H); 7.5-7.6 (lH); 7.7-7.75 (d, lH); 8.0 (d, lH); 8.05 (d, lH); 8.4 p.p.m. (d, lH). Step 4 : Using the procedure of Example l (Step 3) but substituting the compound of Example 3 (Step 3) for the diester of Example l (Step 2) there was obtained the title compound. p.m.r. (CD₃COCD₃) δ: 2.5-2.9 (m, 8H); 5.25 (s, lH); 5.4 (s, 2H); 7.0 (m, lH); 7.l (d, lH); 7.2-7.35 (m, 2H); 7.6 (s, lH); 7.75 (s, lH); 8.0 (d, lH); 8.05 (d, lH); 8.45 p.p.m. (d, lH). EXAMPLE 4 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-8-­ DIMETHYLCARBAMYL-4,6-DITHIAOCTANOIC ACID SODIUM SALT Step l : Preparation of 2-bromomethyl-7-chloro­ quinoline A solution of 7-chloroquinaldine (l77 g, l mole) N-bromosuccinimide (l78 g, l mole), benzoyl­ peroxide (l g) in 2 L CCl₄ were heated at reflux for 2 days under a sun lamp. The reaction mixture was cooled, and passed through a plug of SiO₂ (approx. l Kg) using toluene as eluent. Chromatography on 2 × l kg SiO₂ columns using toluene as eluent afforded ll0-l20 g of the title compound, m.p. ll2⁰(d). p.m.r. (CDCl₃) δ: 8.3 (d,lH) 8.l-7.9 (m,2H), 7.4-7.7 (m,2H), 4.7 p.p.m. (s,2H). Step 2 : Preparation of (7-chloroquinolin-2-yl)-­ methyltriphenylphosphonium bromide To a suspension of 2-bromomethyl-7-chloro­ quinoline (l20 g, 0.5 mol) in 800 mL CH₃CN at 60⁰ was added triphenylphosphine (l83 g). The reaction mixture was heated overnight at 60⁰, cooled and 400 mL ether was added. The solid was filtered and dried to yield l70 g phosphonium salt. p.m.r. (CDCl₃) δ: 7.3-8.2 (m,20H), 6.0 p.p.m. (d,2H). Step 3 : Preparation of dimethyl 5-(3-formylphenyl)-­ 4,6-dithianonanedioate To a solution of isophthalaldehyde (40 g, 0.3 mol.) in chloroform (400 mL) and methyl 3-mercaptopropanoate (68 mL, 0.6 mol.) was added dropwise trimethylsilyl chloride (48 mL, 0.38 mol.) over 30 min. The reaction mixture was stirred at R.T. for 2 hours. The reaction was quenched with 25% aq. NH₄OAc, extracted with ethyl acetate dried and evaporated. Flash chromatography of the residue afforded 50 g of the title compound. p.m.r. (CD₃COCD₃) δ; l0.05 (s,lH), 8.05 (m,lH), 7.85 (t,2H), 7.6 (t,lH), 5.4 (s,lH), 3.6 (s,6H), 2.6-3.0 p.p.m. (m,8H). Step 4 : Preparation of dimethyl 5-(3-(2-(7-chloro­ quinolin-2-yl)ethenyl)phenyl)-4,6-dithianon­ anedioate To a suspension of l90 g phosphonium salt from Step 2 (0.36 mol.) in THF (2 L) at -78⁰ was added l.6 M BuLi (220 mL) dropwise over l.5 hrs. The resulting brown suspension was stirred 30 min at -78⁰. To the suspension was added the aldehyde (Step 3) (ll7 g, 0.32 mol.) in THF (400 mL) dropwise over l.5 hrs. The reaction mixture was allowed to warm to room temperature and quenched with pH 7 buffer (approx. 2 L). Ethyl acetate (l L) was added. The organic phase was seperated, dried and evaporated. Flash chromatography of the residue using 30% ethyl acetate hexane; followed by crystallization with 3:l hexane/ether afforded l35 g of the title compound as a white solid. m.p. 53⁰, p.m.r. (CD₃COCD₃) δ: 8.3 (d,lH), 8.2 (d,lH), 7.8-7.95 (m,4H), 7.6-7.7 (m,2H), 7.4-7.6 (m,3H), 5.4 (s,lH), 3.65 (s,6H), 2.6-3.0 p.p.m. (m,8H). Step 5 : Preparation of methyl 5-(3-(2-(7-chloro­ quinolin-2-yl)ethenyl)phenyl)-8-dimethyl­ carbamyl-4,6-dithiaoctanoate A solution of the aluminum reagent was prepared by adding dropwise l50 mL of 2 M trimethyl­ aluminum in hexane at -20⁰ to a solution of 2 M dimethylamine in toluene (300 mL). The solution was allowed to warm to room temperature. To the diester (step 4) (95 g) in CH₂Cl₂ (l L) was added dropwise l50 mL of the aluminum reagent. The reaction was stirred 7-8 hrs at room temperature. The reaction was carefully quenched at 0⁰ with 2N HCl (until the vigorous reaction subsided); then pH 7 buffer (25% NH₄OAc in H₂O) (l L) and CH₂Cl₂ (l L) were added. The organic phase was separated, dried and evaporated. Flash chromatography of the residue using first 50% ethyl acetate hexane followed by ethyl acetate afforded 38 g recovered di-ester and 38 g desired amide. The recovered di-ester was recycled through the sequence to give l8 g di-ester and l4 g desired amide. Total yield: 52 g of amide. p.m.r. (CD₃COCD₃) δ: 8.3 (d,lH), 7.8-8.0 (m,5H), 7.6-7.7 (d,lH), 7.4-7.65 (m,4H), 5.45 (s,lH), 3.6 (s,6H), 2.95 (s,3H), 2.85 (s,3H), 2.6-3.0 p.p.m. (m,8H). Step 6 : Preparation of 5-(3-(2-(7-chloroquinolin-­ 2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-­ 4,6-dithiaoctanoic acid To the amide (30 g) in 800 mL DME was added l.5 eq lN LiOH (75 mL). The reaction mixture was stirred one hour under N₂. The DME was evaporated. The residue was partitioned between H₂O (500 mL) and ethyl acetate (l L). The aqueous phase was re-extracted with ethyl acetate (500 mL). The aqueous phase was acidified with AcOH and a little 2N HCl to pH 4 and extracted with ethyl acetate (2 × 600 mL). The organic phase was dried and evaporated. The residue was co-evaporated with toluene (300 mL) and triturated with cold ethyl acetate to give l8 g of the acid. m.p. l53-l55⁰, p.m.r. (CD₃COCD₃ + CD₃SOCD₃) δ: 8.4 (d,lH), 7.8-8.05 (m,5H), 7.7 (d,lH), 7.4-7.6 (m,4H), 5.35 (s,lH), 2.95 (s,3H), 2.85 (s,3H), 2.5-2.95 p.p.m. (m,8H). Anal. calc'd. for C₂₆H₂₇ClN₂O₃S₂: C 60.63; H 5.28; N 5.44; S l2.45; Cl 6.88. Found: C 60.43; H 5.23; N 5.63; S l2.56; Cl 6.62. Step 7 To 32 g of acid (Step 6) in ethanol (500 mL) was added NaOH (3l mL of 2N). The reaction mixture was stirred at room temperature l hr and filtered. The filtrate was evaporated and co-evaporated 2× with ethanol and dried on a high vacuum pump. Crystal­ lization from 4:l THF/hexane afforded the title compound as a white solid. p.m.r. (CD₃SOCD₃ + CD₃COCD₃) δ: 8.35 (d,lH), 8.0 (d,lH), 7.95 (d,lH), 7.90 (d,lH), 7.85 (m,2H), 7.3-7.7 (m,5H), 5.28 (s,lH), 2.9 (s,3H), 2.8 (s,3H), 2.55-2.8 (m, 6H), 2.2 p.p.m. (t,2H). EXAMPLE 5 5-(4-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-7-­ (lH-TETRAZOL-5-YL)-3,5-DITHIAHEPTYL)-lH-TETRAZOLE Step l : Preparation of 5-(3-(2-(7-chloroquinolin-­ 2-yl)ethenyl)phenyl)-4,6-dithianona-l,9-­ dinitrile To a solution of 5-(3-(2-(7-chloroquinolin-­ 2-yl)ethenyl)phenyl)-4,6-dithianonadioic acid (Example l) (500 mg) triethylamine in chloroform (ll mL) at -25⁰ was slowly added a solution of ethyl chloroformate (0.7 mL) in chloroform (l0 mL). The reaction was stirred at -25⁰ for 20 min and then ammonia was bubbled into the reaction for 5 minutes, a white solid being formed. The reaction was stirred for l0 min at room temperature and THF (50 mL) was added. The reaction was filtered on celite and evaporated. To the solution of the residue in THF (20 mL) were added slowly pyridine (l.0 mL) followed by trifluoroacetic anhydride (l.0 mL). The reaction was stirred for 20 minutes. A l to l mixture of ethyl acetate and hexane was added to the reaction and it was filtered on a silica gel pad. The solvents were removed by evaporation and the resulting residue was purified by flash chromatography using 30% of ethyl acetate in hexane to afford the title compound as a white solid. p.m.r. ((CD₃)₂CO) δ: 2.8 to 3.l (m,8H), 5.5 (s,lH), 7.4-7.6 (m,3H), 7.7 (d,lH), 7.85-8.05 (m,6H), 8.35 p.p.m. (d,lH). Step 2 : To a solution of 5-(3-(2-(7-chloroquinolin-­ 2-yl)ethenyl)phenyl)-4,6-dithianona-l,9-dinitrile from Step l (290 mg) in acetone (8 mL) was added tri-n-butyltinazide (630 mg). The solvent was removed from the reaction by evaporation and the resulting residue was stirred and heated at l20⁰ for l hour. The reaction was diluted with ethanol (5 mL) and acetic acid (l2 drops). The reaction was stirred 30 minutes at room temperature and ethyl acetate (20 mL), water (20 mL) and aqueous sodium hydroxide 2N (until pH ll) were added. The aqueous layer was separated and acidified with aqueous hydrochloric acid 2N until pH 3. The product was extracted from this aqueous layer using ethyl acetate. The organic layer was then dried over sodium sulfate and evaporated. The residue was purified by flash chromatography using l% of acetic acid in a mixture of 30% ethanol in toluene to afford the title compound which was co-evaporated once with ethanol to give the title compound as a yellow solid. p.m.r. ((CD₃)₂CO) 2.9 to 3.2 (m,4H), 3.3 (t,4H), 5.3(s,lH), 7.4-7.6 (m,5H), 7.5 (d,lH), 7.8-8.0 (m,4H), 8.4 p.p.m. (d,lH). EXAMPLE 6 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-8-­ CARBAMYL-4,6-DITHIAOCTANOIC ACID Using the procedure of Example 4 but substituting ammonia for dimethylamine in Step 5 there was obtained the title compound. p.m.r. (CD₃COCD₃ + CD₃SOCD₃) δ: 8.3 (d,lH), 8.0 (d,lH),7.95 (d,lH), 7.8-7.9 (m,4H), 7.7 (m,lH), 7.4-7.6 (m,4H), 5.3 (s,lH), 2.7-3.0 (m,4H), 2.6 (m,2H), 2.45 p.p.m. (m,2H). EXAMPLE 7 N-[8-CARBOXYL-5-(3-(2-(7-CHLOROQUINOLIN-2-2L)ETHENYL)-­ PHENYL)-4,6-DITHIAOCTANOYL)GLYCINE Using the procedure of Example l6 but substi­ tuting methyl glycinate for t-butylamine in Step 3 is obtained the title compound as a methyl ester. The ester is hydrolyzed to the title compound. EXAMPLE 8 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-­ 4,6-DITHIA-8-METHYLCARBAMOYLOCTANOIC ACID Using the procedure described in Example 4 but substituting methylamine for dimethylamine in Step 5 there was obtained the title compound. p.m.r. (CD₃COCD₃) δ: 8.35 (d,lH), 8.05 (d,lH), 7.85-7.95 (m,4H), 7.65 (dd,lH), 7.4-7.6 (m,4H), 7.l (bs,lH), 5.30 (s,lH), 2.6-3.0 (m,9H), 2.50 p.p.m. (t,2H). EXAMPLE 9 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-8-­ DIETHYLCARBAMYL-4,6-DITHIAOCTANOIC ACID Using the procedure described in Example 4 but substituting diethylamine for dimethylamine in Step 5 there was obtained the title compound. p.m.r. (CD₃COCD₃) δ: 8.3 (d,lH), 7.7-8.0 (m,5H), 7.3-7.6 (m,5H), 5.2 (s,lH), 3.l-3.3 (m,4H), 2.4-2.7 (m,6H), 2.0 (t,3H), l.9-2.l p.p.m. (m,6H). EXAMPLE l0 5-(3-(7-CHLOROQUINOLIN-2-YLMETHOXY)PHENYL)-8-DIMETHYL­ CARBAMYL-4,6-DITHIAOCTANOIC ACID Using the procedure described in Example 4, Steps 5 and 6 but substituting the diester from Example 3, Step 3 for the diester from Example 4, Step 4 there was obtained the title compound. p.m.r. (CD₃COCD₃) δ: 8.35 (d,lH), 7.95 (dd,lH), 7.9 (d,lH), 7.5-7.65 (m,2H), 7.2 (t,lH), 7.05 (bs,lH), 6.9 (m,2H), 5.28 (s,2H), 5.l (s,lH), 2.8 (s,3H), 2.7 (s,3H), 2.2-2.7 p.p.m. (m,8H). EXAMPLE ll 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-4,6-­ DITHIA-8-MORPHOLINOCARBAMYL-OCTANOIC ACID Using the procedure of Example 4 but substituting morpholine for dimethyl amine in Step 5 there was obtained the title compound. ¹H NMR (250 MHz, CDCl₃) δ: 2.6 (2H, t, J = 6Hz), 2.7 (2H, t, J = 6Hz), 2.8-3.05 (4H, complex m), 3.38 (2H, t, J = 4 Hz), 3.6 (6H, s(b)), 5.l (lH, s), 7.l5-7.80 (9H, complex m), 8.l (2H, d, J = 6Hz), 8.7 (lH, s(b), exchangeable). Anal. Calc'd. for C₂₈H₂₉ClN₂O₄S₂: C, 60.36; H, 5.25; N, 5.03; S, ll.5l; Cl,6.36 Found: C, 60.40; H, 5.32; N, 4.86; S, ll.37 Cl,6.66. EXAMPLE l2 4-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-3,5-­ DITHIAHEPTADIOIC ACID Using the procedure of Example l but substituting methyl 2-mercaptoacetate for methyl 3-mercaptopropanoate in Step l there was obtained the title compound. p.m.r. (CD₃SOCD₃) δ: 3.3 (m,4H), 5.25 (s,lH), 7.25-7.95 (m,l0H), 8.30 p.p.m. (d,lH). EXAMPLE l3 4-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-6-­ DIMETHYLCARBAMYL-3,5-DITHIAHEXANOIC ACID Using the procedure of Example 4 by sub­ stituting methyl 2-mercaptoacetate for methyl 3-mer­ captopropanoate in Step 3 there was obtained the title compound. ¹H NMR (250 MHz, CDCl₃) δ: 2.9 (s,3H), 3.0 (s,3H), 3.3-3.5 (4 peaks, 2H), 3.65 (d,2H), 5.5 (s,lH), 7.2-7.65 (m,7H), 7.7 (d, lH, J = 6Hz), 7.8 (s,lH), 8.05--8.l0 (m,2H), 8.8 (s, lH, exchangeable). Anal. Calc'd. for C₂₄H₂₃ClN₂O₃S₂: C, 59.l8; H, 4.76; N, 5.75; S, l3.l7 Cl, 7.28. Found: C, 59.36; H, 4.96; N, 5.39; S, l2.98; Cl, 7.26. EXAMPLE l4 5-(3-(2-(QUINOLIN-2-YL)ETHENYL)PHENYL)-4,6-DITHIANO­ NANEDIOIC ACID Using the procedure described in Example l but substituting quinaldine for 7-chloroquinaldine in Step l there was obtained the title compound. p.m.r. (CD₃COCD₃) δ: 8.3 (d,lH), 7.4-8.0 (m,llH), 5.35 (s,lH), 2.7-3.0 (m,4H), 2.6 p.p.m. (m,4H). EXAMPLE l5 5-(3-(2-(6,7-DICHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-4,6-­ DITHIANONANEDIOIC ACID Using the procedure described in Example l but substituting 6,7-dichloroquinaldine for 7-chloroquinaldine in Step l there was obtained the title compound. p.m.r. (CD₃SOCD₃) δ: 8.3 (d,lH), 8.l5 (d,2H), 7.8-8.0 (m,3H), 7.65 (bd,lH), 7.4-7.7 (m,3H), 5.35 (s,lH), 2.5-3.0 p.p.m. (m,8H). EXAMPLE l6 8-t-BUTYLCARBAMYL-5-(3-(7-CHLOROQUINOLIN-2-YLMETHOXY)­ PHENYL)-4,6-DITHIAOCTANOIC ACID Step l : Preparation of 3-(7-chloroquinolin-2-yl-­ methoxy)benzaldehyde A mixture of the bromide (Example 4, Step l) (l09 g) and m-hydroxybenzaldehyde (45 g) and K₂CO₃ (96 g) in acetone l.5 L were heated at 80⁰ with stirring in an oil bath for l.5 hours. The reaction mixture was cooled, CH₂Cl₂ (600 mL) was added, and the mixture was filtered and evaporated. Trituration of the residue with 7:l ether/hexane afforded the title compound which was used as such for the next step. p.m.r. (CDCl₃, 250 MHz) δ 9.55 (s,lH), 8.2 (d,lH), 8.l0 (d,lH), 7.75 (d,lH), 7.65 (d,lH), 7.4-7.6 (m,4H), 7.28 (m,lH), 5.4 p.p.m. (s,2H). Step 2 : Preparation of 5-(3-(7-chloroquinolin-2-yl-­ methoxy)phenyl)-4,6-dithianonanedioic acid A mixture of aldehyde (Step l) (9l g, .3 mol.) in benzene (l.5 L), 3-mercaptopropanoic acid (l00 mL) and toluene sulfonic acid (l7 g) were refuxed with a Dean Stark trap for 4 hrs. The reaction mixture was cooled. The mixture was dissolved with lN NaOH (l L). The organic layer was separated and discarded. The aqueous layer was acidified to pH 6 with 2N HCl and extracted with ethyl acetate (2 × l L). The organic layer was dried and evaporated. Swishing the residue with ether (2 × l L) and filtration afforded the title di-acid (ll0 g). m.p. l42⁰ p.m.r. (CD₃COCD₃ + CD₃SOCD₃, 250 MHZ) δ: 8.45 (d,lH), 8.0-8.l (m,2H), 7.75 (d,lH), 7.63 (dd,lH), 7.25-7.35 (m,4H), 7.l5 (d,lH), 7.0 (dd,lH), 5.4 (s,2H), 5.25 (s,lH), 2.6-2.9 (m,4H), 2.55 p.p.m. (t,4H). Step 3 : To a solution of di-acid (Step 2) (55 g, 0.ll4 mol.), triethylamine (35 mL), in CH₂Cl₂ (2.8 l) and CH₃CN (500 mL) at 0⁰ was added 2-chloro-l-methylpyridinium iodide (32 g, .l26 m). The suspension was stirred l hr at 0⁰ to afford a yellow solution . To this solution was added t-butylamine (l4 mL). The reaction was stirred at room temperature overnight. The mixture was then evaporated, and partitioned between ethyl acetate and H₂O. The aqueous phase was adjusted to pH 3-4 before extraction. The organic phase was dried and evaporated. Flash chromatography of the residue using l5% acetone and 0.2% AcOH in toluene afforded the title compound as an oil. Trituration with ethanol afforded the title compound as a white solid which was further purified by swishing in ether. p.m.r. (CD₃COCD₃, 250 MHz) 8.25 (d,lH), 7.95 (d,lH), 7.8 (d,lH), 7.65 (d,lH), 7.55 (dd,lH), 7.l-7.3 (m,3H), 7.05 (s,lH), 6.9 (m,lH), 5.3 (s,2H), 5.l (s,lH), 2.7-3.0 (m,4H), 2.3-2.5 (m,4H), l.3 p.p.m. (s,9H). Anal. Calc'd. for C₂₇H₃₁ClN₂O₄S₂: C 59.27; H 5.7l; N 5.l2; S ll.72. Found: C 58.7l; H 5.97; N 5.l2; S ll.78. EXAMPLE l7 8-CARBAMYL-5-(3-(7-CHLOROQUINOLIN-2-YLMETHOXY)PHENYL)-­ 4,6-DITHIAOCTANOIC ACID The diacid (Example 3) (3.954 g, 8.04 mmoles) was dissolved in 250 mL CH₂Cl₂:CH₃CN 4:l. Triethylamine (2.5 mL, 2.2 equiv.) was added followed, at 0⁰C, by 2-chloro-l-methylpyridinium iodide (2.257 g, l.l equiv.). After stirring l hour at 0⁰C, ammonia was added and the mixture stirred for another hour at l0⁰C. Water was then added and the aqueous layer acidified to pH 5. Extraction with CH₂Cl₂ (2×) and EtOAc (2×) and flash chromato­ graphy of the residue on silica with acetone: CH₂Cl₂:AcOH 40:60:l and 50:50:l afforded the title compound. ¹H NMR (CD₂Cl₂:DMSO) δ: 2.23 (t,2H), 2.32 (t,2H), 2.44-2.68 (m,4H), 4.90 (s,lH), 5.20 (s,2H), 6.33 (broad s,lH), 6.77 (dd,lH), 6.89 (d,lH), 6.98-7.l4 (m,3H), 7.38 (dd,lH), 7.53 (d,lH), 7.74 (d,lH), 7.88 (d,lH), 8.l5 (d,lH), p.p.m. EXAMPLE l8 5-(3-(7-CHLOROQUINOLIN-2-YLMETHOXY)PHENYL)-4,6-DITHIA-­ 8-METHYLCARBAMYLOCTANOIC ACID Using the procedure described in Example l6 by replacing methylamine for t-butylamine in Step 3 there was obtained the title compound. p.m.r. (CD₃COCD₃) δ: 8.4 (d,lH), 8.05 (d,lH), 8.05 (d,lH), 7.75 (d,lH), 7.6 (dd,lH), 7.4 (bs,lH), 6.95-7.30 (4H), 5.2 (s,lH), 5.4 (s,lH), 2.6-2.9 (m,7H), 2.6 (t,2H), 2.4 p.p.m. (t,2H). EXAMPLE l9 5-(3-(3-(7-CHLOROQUINOLIN-2-YL)PHENYL)-4,6-­ DITHIANONANEDIOIC ACID DISODIUM SALT Step l : Preparation of 3-ethenylbenzaldehyde To a suspension of methyltriphenylphos­ phonium bromide (27.2 g) in THF (200 mL) at 0⁰ was added dropwise n-butyllithium (47 mL of l.6 M in hexane). The reaction mixture was stirred 30 min at 0⁰ and cooled to -l0⁰. The reaction mixture at -l0⁰ was transferred dropwise through a canula to a solution of isophthalaldehyde (l0.0 g) in THF (300 mL) at -50⁰. The reaction was allowed to warm up to room temperature. After 3.5 hours at room temperature the reaction mixture was quenched with NH₄OAc buffer (200 mL). The reaction mixture was extracted with ethyl acetate, dried over sodium sulfate and evaporated. Flash chromatography of the residue starting with l0% and finishing with l5% of diethyl ether in hexane afforded the title compound. p.m.r. ((CD₃)₂CO) δ: 5.37 (d,lH), 5.96 (d,lH), 6.87 (dd,lH), 7.58 (t,lH), 7.82 (m,2H), 8.00 (t,lH), l0.06 p.p.m. (s,lH). Step 2 : Preparation of 2-(3-ethenylphenyl)-l,3-­ dioxolane To a solution of 3-ethenylbenzaldehyde from Step l (3.77 g) and ethylene glycol (l.8 mL) in benzene (40 mL) was added p-toluenesulfonic acid monohydrate (l00 mg). The reaction mixture was heated to reflux for 6 hours. The water produced by the reaction was collected in a Dean-Stark trap. The reaction was allowed to cool to room temperature. The reaction was diluted with NH₄OAc buffer and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated. Flash chromatography of the residue using l5% diethyl ether in hexane afforded the title compound. p.m.r. ((CD₃)₂CO) δ: 4.0 (m,4H), 5.4 (d,lH), 5.27 (s,lH), 5.83 (d,lH), 6.77 (dd,lH), 7.35 (bs,2H), 7.45 (bm, lH), 7.54 p.p.m. (bs,lH). Step 3 : Preparation of 2-(3-(2-hydroxethyl)phenyl)-­ l,3-dioxolane To a solution of 2-(3-ethenylphenyl)-­ l,3-dioxolane from Step 2 (4.l4 g) in THF (25 mL) was slowly added a solution of borane-tetrahydrofuran complex (8.3 mL of 0.98 M solution in THF) at such a rate as to maintain the temperature of the reaction below 35⁰. A solution of aqueous sodium hydroxyde (2.5 mL of 3N) was carefully added followed by a solution of hydrogen peroxide (2.5 mL of 30% w/v in water). The reaction was stirred at room temperature for 30 min. A saturated aqueous solution of sodium chloride was added and the reaction was extracted with ethyl acetate. The organic layer was separated, dried over sodium sulfate and evaporated. Purification of the residue, by flash chromatography using 45% ethyl acetate in hexane afforded the title compound. p.m.r. ((CD₃)₂CO) δ: 2.82 (t,2H), 3.73 (m,2H), 3.76 (t-lH), 4.02 (m,4H), 5.70 (s,lH), 7.27 (m,3H), 7.33 p.p.m. (bs,lH). Step 4 : Preparation of 3-(,3-dioxolane-2-yl)-­ phenylacetaldehyde To a solution of pyridine (7.5 mL) in dichloromethane (ll0 mL) at l0⁰ was added chromium trioxide (4.85 g) and celite (l6.0 g). After l5 minutes of stirring at l0⁰, a solution of the alcohol from Step 3 (l.ll g) in dichloromethane (ll mL) was added to the reaction. The resulting brown suspension was stirred for 20 min and sodium bisulfate (l0 g) was added. After 30 min, diethyl ether (l50 mL) was added and the reaction was vigorously stirred. The reaction was filtered on a pad of magnesium sulfate covered with silica gel. The solid removed by filtration was washed with diethyl ether (2 × 50 mL). Evaporation of the filtrate gave a colorless oil used as such in the next step. Step 5 : Preparation of 2-(3-(3-(7-chloroquinolin-­ 2-yl)prop-2[E]-enyl)phenyl-l,3-dioxolane To a suspension of (7-chloroquinolin-­ 2-yl)methyltriphenylphosphonium bromide (Example 4, Step 2) (2.70 g) in THF (30 mL) at -78⁰ was added dropwise over 30 min a solution of butyl lithium (3.2 mL of l.6 M in hexane) to give a deep red-orange solution. A solution of the aldehyde from step 4 (0.85 g) in THF (l0 mL) was added dropwise to the reaction at -78⁰. The reaction was stirred at -78⁰ for l5 min and at room temperature for 45 min. The reaction was quenched with NH₄OAc buffer, extracted with ethyl acetate, dried over sodium sulfate and evaporated. The residue was purified by flash chromatography using l5% ethyl acetate in hexane to afford the title compound. p.m.r. ((CD₃)₂CO) δ: 3.7 (dd,2H), 4.0 (m,4H), 5.7 (s,lH), 6.8 (dt,lH), 7.l (dt,lH), 7.3 (m,3H), 7.4 (s,lH), 7.5 (dd,lH), 7.7 (d,lH), 7.9 (m,2H), 8.3 p.p.m. (d,lH). Step 6 : Preparation of 2-(3-(3-(7-chloroquinolin-­ 2-yl)propyl)phenyl-l,3-dioxolane To a solution of 2-(3-(3-(7-chloroquinolin-­ 2-yl)prop-2[E]-enyl)phenyl)-l,3-dioxolane from Step 5 (l68 mg) in a l to l mixture of ethyl acetate and hexane (l2 mL) was added 5% rhodium-on-carbon (58 mg). The resulting black suspension was stirred under an atmosphere of hydrogen for 3.5 hours. The reaction was filtered on a pad of silica gel, washed with ethyl acetate (5 mL) and evaporated. The residue was purified by flash chromatography using l5% ethyl acetate in hexane to afford the title compound. p.m.r. ((CD₃)₂CO) δ: 2.2 (m,2H), 2.7 (t,2H), 3.0 (t,2H), 4.0 (m,4H), 5.7 (s,lH), 7.3 (m,3H), 7.35 (s,lH), 7.45 (d,lH), 7.5 (dd,lH), 7.9 (d,lH), 7.95 (d,lH), 8.25 p.p.m. (d,lH). Step 7 : Preparation of 3-(3-(7-chloroquinolin-­ 2-yl)propyl)benzaldehyde To a solution of 2-(3-(3-(7-chloroquinolin-­ 2-yl)propyl)phenyl)-l,3-dioxolane from Step 6 (l89 mg) in THF (9.5 mL) was added a l to l mixture of acetic acid and water (6.5 mL). The reaction was heated at 63⁰ for 2 hours. The reaction was diluted with ethyl acetate and the organic layer washed with saturated aqueous solution of sodium bicarbonate. The organic layer was dried over sodium sulfate and evaporated. The residue was co-evaporated once with toluene to afford the title compound. p.m.r. ((CD₃)₂CO) δ: 2.2 (m,2H), 2.8 (t,2H), 3.0 (t,2H), 7.5 (m,3H), 7.6 (m,lH), 7.7 (dd,lH), 7.8 (m,lH), 7.9 (d,lH), 8.0 (d,lH), 8.3 (d,lH), l0.0 p.p.m. (s,lH). Step 8 : To a solution of 3-(3-(7-chloroquinolin-­ 2-yl)propyl)benzaldehyde from Step 7 (l67 mg) in toluene (6 mL) was added 3-mercaptopropanoic acid (l90 µL) and p-toluenesulfonic acid monohydrate (60 mg). The reaction was heated to reflux and the water produced by the reaction was removed with a Dean-Stark trap. The reaction was allowed to cool to room temperature and it was diluted with dichloromethane. Acetic acid was added to help to disolve the sticky residue. The reaction was washed with NH₄OAc buffer and the organic layer was dried over sodium sulfate and evaporated. The residue was purified by flash chromatography using 0.5% of acetic acid in a mixture of 30% of THF in toluene. The resulting product was co-evaporated twice with ethanol and foamed by co-evaporation twice with acetone to yield the free acid. p.m.r. ((CD₃)₂CO) δ: 2.2 (m,2H), 2.6 (t,4H), 2.7-3.0 (m,8H), 5.3 (s,lH), 7.l-7.35 (m,3H), 7.4 (s,lH), 7.5 (d,lH), 7.55 (dd,lH), 7.9 (d,lH), 8.l (d,lH), 8.3 p.p.m. (d,lH). Dissolution of the acid in ethanol, addition of aqueous sodium hydroxide (0.45 mL of 2N) and co-evaporation twice with ethanol afforded the title compound as a light-yellow solid. EXAMPLE 20 SODIUM 5-(3-(7-CHLOROQUINOLIN-2-YLMETHYLTHIO)­ PHENYL)-8-DIMETHYLCARBAMYL-4,6-DITHIAOCTANOATE Step l : Preparation of 3-(methylthio)phenylbromide To a solution of 3-bromothiophenol (l0 g) in acetone (250 mL) was added potassium carbonate (l4.6 g) and iodomethane (4.28 mL). The heterogenous mixture was refluxed for 4 hrs., cooled to room temperature, filtered, and concentrated under reduced pressure. Ether (200 mL) was added, and the mixture was filtered again and finally evaporated to dryness to yield the title compound.. ¹H NMR (CDCl₃) δ: 2.46 (s,3H), 7.l0-7.55 (m,4H). Step 2 : Preparation of 3-(methylthio)benzaldehyde Magnesium (l.34 g) was flushed with nitrogen for 30 minutes, then heated with a flame. After cooling down to room temperature, THF (35 mL) was added. A small amount of 3-(methylthio)phenylbromide from Step l (ll.l7 g/25 mL THF) was added then a crystal of I₂. After the reaction had started, the rest of the bromo compound was added. The mixture was stirred at room temperature for 4 hrs. Then triethyl orthoformate (30 mL/l0 mL THF) was added and the solution was refluxed for 78 hrs. After cooling to room temperature, lN HCl was added, the mixture was stirred for l hr, then extracted with ether, washed with brine, dried over Na₂SO₄, filtered and evaporated to dryness. Purification by chromato­ graphy afforded 3-(methylthio)benzaldehyde. Step 3 : Preparation of 3-(7-chloroquinolin-­ 2-ylmethylthio)benzaldehyde To 3-(methylthio)benzaldehyde (l.8 g) in CHCl₃ at 0⁰C was slowly added 3-chloroperoxybenzoic acid (2.48 g). The mixture was stirred for l hr at 0⁰C then warmed-up to room temperature. Calcium hydroxide (l.3 g) was added and the suspension was stirred for 20 min at room temperature then filtered over celite and evaporated to dryness. To the oily residue trifluroacetic anhydride (20 mL) was added, and evaporated under reduced pressure. This process was repeated. To the oily residue 75 mL of 0.4N sodium hydroxide and 75 mL of methanol were added with vigorous stirring. The solution was extracted with ether, dried Na₂SO₄, filtered and evaporated to dryness. The residue was dissolved in 20 mL of acetone, potassium carbonate (l.26 g) and 2-bromo­ methyl-7-chloroquinoline from Example 4, Step l (l.5 g) were added. The mixture was refluxed for l5 min, then cooled to room temperature, ether was added, the organic layer was washed with brine (3×), dried over sodium sulfate, filtered and evaporated to dryness. Purification by chromatography afforded the title compound. ¹H NMR (CDCl₃) δ: 4.48 (s,2H), 7.38-8.ll (m,9H), 9.93 (s,lH). Step 4 : Preparation of 5-(3-(7-chloroquinolin-2-yl­ methylthio)phenyl)-4,6-dithianonanedioic acid To a solution of aldehyde (Step 3) (500 mg) in toluene (l5 mL) was added 3-mercaptopropionic acid (0.56 mL) and p-toluene sulfonic acid (l53 mg). The solution was refluxed for 6 hrs in a flask equipped with a Dean-Stark apparatus filled with 3 © molecular sieve. The solution was cooled to room temperature, methylene chloride was added, the organic layer was washed with acidified 25% ammonium acetate, dried over sodium sulfate filtered and evaporated to dryness to afford the title compound. ¹H NMR (CDCl₃) δ: 2.62-2.98 (m,8H), 4.46 (s,2H), 5.00 (s,lH), 7.08-8.08 (m,9H). Step 5 : To a solution of diacid (Step 4) (360 mg) in dichloromethane (28 mL) and acetonitrile (7.l mL) was added 2-chloro-l-methylpyridinium iodide (227 mg). The solution was cooled to 0 C and triethylamine (l23 µL) was added. After stirring for l5 min, 0.42 mL of a 2M solution of dimethylamine in toluene was added. The solution was stirred l hr at room temperature, washed with acidified 25% ammonium acetate, dried over sodium sulfate, filtered and evaporated to dryness. To the oil obtained after chromatography, in 2 mL of ethanol, was added 0.l54 mL of 2N NaOH. After evaporating to dryness the title compound was obtained as a foam. ¹H NMR δ: 2.52-2.96 (m,8H), 2.92 (s,6H), 4.42 (s,2H), 4.96 (s,lH), 7.l0-8.l2 (m,9H). EXAMPLE 2l 8-CARBAMYL-5-(3-(7-CHLOROQUINOLIN-2-YLMETHYLTHIO)­ PHENYL)-4,6-DITHIAOCTANOIC ACID To 500 mg of diacid (Example 20, Step 4) in dichloromethane (39 mL) and acetonitrile (9.9 mL) at 0⁰C was added 2-chloro-l-methylpyridinium iodide (3l5 mg). After l5 min triethylamine (l70 µL) and l0 mL of a saturated solution of ammonia in ether were added. The solution was stirred l hr at room temperature then it was washed with acidified 25% ammonium acetate, extracted with ethyl acetate, dried over sodium sulfate, filtered and evaporated to dryness. Purification by chromatography afforded the title compound. m.p. l4l-l42⁰C, ¹H NMR (CDCl₃) δ: 2.44 (t, J = 7Hz, 4H), 2.68 (m,2H), 2.92 (m,2H), 4.4l (s,2H), 4.94 (s,lH), 5.58(s,lH), 6.l6 (s,lH), 7.l4-8.l2 (m,9H). EXAMPLE 22 N-t-BUTYL-8-(lH-TETRAZOL-5-YL)-5-(3-(7-CHLOROQUINOLIN-­ 2-YLMETHOXY)PHENYL)-4,6-DITHIAOCTAMIDE Step l : Preparation of 5-(3-(7-chloroquinolin-2-yl-­ methoxy)phenyl)-8-cyano-4,6-dithiaoctanoic acid To the amide acid (Example l7) (2.788 g, 3.63 mmoles) in THF (40 mL) at -23⁰C, pyridine (2.2 mL, 7.5 equiv.) and trifluoroacetic anhydride (l.l mL, 2.2 equiv.) were added. After one hour of stirring at 0⁰C, l0% HCl was added, the mixture was extracted with EtOAc, dried over sodium sulfate and evaporated. Flash chromatography on silica with EtOAc:toluene:AcOH 30:70:l afforded l.447 g of the title compound. IR (neat) ν 3600-2500 (COOH), 2245, l705, l600, l495 cm⁻¹; ¹H NMR (CD₃COCD₃) δ: 2.6l (t,2H), 2.68-2.97 (m,6H), 5.32 (s,lH), 5.38 (s,2H), 7.02 (dd,lH), 7.08-7.33 (m,3H), 7.54 (dd,lH), 7.70 (d,lH), 7.94 (d,lH), 8.03 (broad s,lH), 8.35 p.p.m. (d,lH). Step 2 : Preparation of N-t-butyl-5-(3-(7-chloro­ quinolin-2-yl-methoxy)phenyl)-8-cyano-4,6-­ dithiaoctanamide Dimethylformamide (50 µL) was added to a solution of the crude cyanoacid (step l) (l.447 g) in CH₂Cl₂ (25 mL), followed, at 0⁰C, by oxalyl chloride (400 µL). The solution was stirred at room temperature for l5 minutes. At 0⁰C, t-butyl­ amine (3.3 mL) was then added and the mixture stirred at room temperature 2 hours. Addition of 25% aqueous NH₄OAc, extraction with EtOAc, drying, evaporation, and flash chromatography on silica with ethyl acetate:toluene 25:75 and 30:70 afforded the title compound. ¹H NMR (CD₃COCD₃) δ: l.30 (s,9H), 2.36 (t,2H), 2.65-2.95 (m,6H), 5.29 (s,lH), 5.39 (s,2H), 6.74 (broad s,lH), 7.02 (dd,lH), 7.09-7.35 (m,3H), 7.59 (dd,lH), 7.73 (d,lH), 8.0l (d,lH), 8.04 (broad s,lH), 8.40 (d,lH) p.p.m. Step 3 : The cyanoamide (step 2) (503 mg) was mixed with tributyltin azide (566 mg, l.5 equiv.) and heated at l20⁰C for 4 hours. Flash chromatography of the crude reaction mixture on silica using THF:toluene: AcOH 30:70:l afforded the title compound. ¹H NMR (CD₃COCD₃) δ: l.35 (s,9H), 2.45-2.53 (m,2H), 2.64-2.76 (m,lH), 2.86-3.05 (m,3H), 3.29 (t,2H), 5.l7 (s,lH), 5.38 (s,2H), 6.98-7.09 (m,2H), 7.l8-7.2l (m,2H), 7.30 (dd,lH), 7.6l (dd,lH), 7.76 (d,lH), 8.0l (d,lH), 8.05 (broad s,lH), 8.42 (d,lH) p.p.m. EXAMPLE 23 8-CARBAMYL-5-(3-(7-CHLOROQUINOLIN-2-YLMETHOXY)PHENYL)-­ 4,6-DITHIAOCTANAMIDE Using the procedure described in Example l6 by replacing l eq 2-chloro-l-methyl pyridinium iodide by 2 eq of 2-chloro-l-methylpyridinium iodide and t-butylamine by excess ammonia gas in Step 3 there was obtained the title compound. p.m.r. (CD₃SOCD₃) δ: 8.3 (d,lH), 8.0 (d,lH), 7.9 (d,lH), 7.7 (d,lH), 7.5 (dd,lH), 7.0-7.3 (m,3H), 7.0 (d,lH), 6.9 (bd,lH), 6.7 (bs,lH), 5.3 (s,2H), 5.05 (s,lH), 2.6-2.85 (m,4H), 2.36 p.p.m. (t,4H). EXAMPLE 24 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)CYCLOPROPYL)PHENYL)-­ 4,6-DITHIANONANEDIOIC ACID Step l : Preparation of 3-(2-(7-chloroquinolin-2-yl)-­ ethenyl)benzaldehyde A solution of isophthalaldehyde (4.0 g) and 7-chloroquinaldine (5.39 g) in acetic anhydride was heated at l25⁰ in an oil bath for 48 hours. The reaction was cooled to room temperature, diluted with ether (30 mL) and the resulting suspension was stirred vigorously. The solid title compound was collected by filtration and was used as such in the next step. Step 2 : Preparation of 2-(3-(2-(7-chloroquinolin-­ 2-yl)ethenyl)phenyl)-l,3-dioxolane A mixture of 3-(2-(7-chloroquinolin-­ ethenyl)benzaldehyde (step l) (938 mg, 3.l9 mmoles), ethylene glycol (200 µL, l.l5 equiv.), p-toluene­ sulfonic acid (296 mg, 0.5 equiv.) and toluene (l.5 mL) was heated at reflux overnight. 25% aqueous NH₄OAc was then added and the mixture extracted with EtOAc. Flash chromatography of the residue on silica with EtOAc:hexane 20:80 afforded the title compound. ¹H NMR (CD₃COCD₃) δ: 4.00-4.20 (m,4H), 5.80 (s,lH), 7.42-7.56 (m,4H), 7.74 (m,lH), 7.80-8.03 (m,5H), 8.33 (d,lH) p.p.m. Step 3 : Preparation of 2-(3-(2-(7-chloroquinolin-­ 2-yl)cyclopropyl)phenyl)l,3-dioxolane To a solution of trimethylsulfonium iodide (2.l28 g, l0.4 mmoles) in 20 mL of anhydrous THF at -l0⁰C was added dropwise a solution of n-butyl­ lithium l.6 M in hexanes (4.9 mL, 0.75 equiv.). Then the temperature was raised to 2l⁰C for 2 hours. To this mixture cooled to 0⁰C, the alkene (step 2) (967 mg, 2.86 mmoles) in 5 mL THF was added and the solution stirred overnight. Hydrolysis with 25% aqueous NH₄OAc, extraction with EtOAc and flash chromatography on silica using EtOAc:toluene 2.5:97.5 afforded the title compound. ¹H (CD₃COCD₃) δ: l.6l (m,lH), l.94 (m,lH), 2.56 (m,lH), 2.70 (m,lH), 3.93-4.l4 (m,4H), 5.7l (s,lH), 7.2l-7.36 (n,4H), 7.48 (dd,lH), 7.55 (d,lH), 7.90 (d,lH), 7.92 (s,lH), 8.2l (d,lH) p.p.m. Step 3 : Preparation of 3-(2-(7-chloroquinolin-­ 2-yl)cyclopropyl)benzaldehyde The dioxolane (step 3) (500 mg, l.42 mmoles) was heated at reflux in 9 mL of THF:AcOH:H₂O 6:2:l for 2 hours. Addition of 25% NH₄OAc, extraction with EtOAc, drying, evaporation, and flash chromatography on silica with EtOAc:toluene 2.5:97.5 afforded the title compound. ¹H NMR (CD₃COCD₃) δ: l.67 (m,lH), 2.00 (m,lH), 2.67 (m,lH), 2.8l (m,lH), 7.46-7.63 (m,4H), 7.72-7.8l (m,2H), 7.90-7.95 (m,2H), 8.24 (d,lH), l0.04 (s,lH) p.p.m. Step 4 : A solution of aldehyde (step 4) (387 mg, l.26 mmoles), 3-mercaptopropionic acid (440 µL, 4 equiv.) and p-toluenesulfonic acid (l26 mg, 0.5 equiv.) in toluene (6 mL) was heated at reflux for 4:30 hours using a Dean-Stark trap to remove water. To the cooled reaction mixture 50 mL of 25% NH₄OAc and 4 mL of AcOH were added. Extraction with CH₂Cl₂, drying, evaporation, and flash chromatography on silica with acetone:CH₂Cl₂:AcOH l5:85:l afforded the title compound. ¹H NMR (CD₃COCD₃) δ: l.62 (m,lH), l.94 (m,lH), 2.59 (t,4H), 2.64-2.94 (m,6H), 5.25 (s,lH), 7.l2-7.4l (m,4H), 7.48 (d,lH), 7.56 (d,lH), 7.89-7.95 (m,2H), 8.23 (d,lH) p.p.m.; MS 50l (M⁺), 395 (M-C₃H₆SO₂), 322 (M-C₃H₆SO₂-C₃H₅O₂), l77. EXAMPLE 25 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHYL)PHENYL)-4,6-­ DITHIANONANEDIOIC ACID Step l : Preparation of 3-(2-(7-chloroquinolin-­ 2-yl)ethyl)benzonitrile To a solution of 7-chloroquinaldine (l7.7 g) in THF (80 mL) at -78⁰ was added a solution of l00 mL lithium diisopropyl amide (LDA) (lM) dropwise. After addition the solution was warmed to -20⁰ and added dropwise to 3-cyanobenzyl bromide (20 g) in THF (80 mL) at 0⁰. The reaction mixture was stirred l hr at 0⁰ and warmed to room temperature (30 min). The mixture was partitioned between pH 7 buffer (25% NH₄OAc) and ethyl acetate. The organic layer was dried and evaporated. Flash chromatography of the residue using 30% ether in hexane afforded the title compound. p.m.r. (CDCl₃) δ: 8.l (d,lH), 7.9 (d,lH), 7.0-7.8 (m,7H), 3.2 p.p.m. (m,4H). Step 2 : Preparation of 3-(2-(7-chloroquinolin-­ 2-yl)ethyl)benzyaldehyde To the cyanide (Step l, l0g) in formic acid (200 mL) at l00⁰ was added portionwise Ni-Al alloy (3 g). The reaction mixture was heated at ll0⁰ for 6 hrs, filtered and evaporated. The residue was partitioned between NaHCO₃ (aq) and ethyl acetate, and the organic layer was dried and evaporated. Flash chromatography using 30% ether in hexane afforded the title compound. p.m.r. (CDCl₃) δ: 9.9 (s,lH), 8.l (d,lH), 7.9 (d,lH), 7.0-7.8 (m,7H), 3.2 p.p.m. (m, 4H). Step 3 : A solution of aldehyde (Step 2, 2g), 3-mercaptopropionic acid (4 mL) and TsOH (.5 g) in toluene (25 mL) was heated 8 hrs at reflux using a Dean Stark trap. The mixture was partitioned between pH 7 buffer (l00 mL), acetic acid (5 mL) and CH₂Cl₂ (500 mL). The organic layer was dried (Na₂SO₄) and evaporated. Flash chromatography of the residue using l5% THF in toluene with 0.5% AcOH afforded the title compound. m.p. l60-l6l⁰ p.m.r. (CD₃COCD₃) δ: 8.25 (d,lH), 8.0 (d,lH), 7.95 (d,lH), 7.55 (dd,lH), 7.45 (d,lH), 7.4 (bs,lH), 7.l5-7.35 (m,3H), 5.20 (s,lH), 2.95-2.75 (m,4H), 2.65-2.85 (m,4H), 2.50 p.p.m. (t,4H). EXAMPLE 26 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHYL)PHENYL)-8-­ DIMETHYLCARBAMYL-4,6-DITHIAOCTANOIC ACID To a suspension of diacid (Example 25) (0.3 g) in dichloromethane (20 mL), acetonitrile (5 mL) and triethylamine (200 µL) was added 2-chloro-l-­ methylpyridinium iodide (l80 mg). The mixture was stirred 30 min, cooled to 0⁰ and 0.32 mL of a 2M solution of dimethylamine in toluene was added. The reaction was stirred 2 hours at room temperature. The reaction mixture was poured onto NH₄OAc buffer and acetic acid (5 mL) was added. The mixture was extracted with ethyl acetate, which was dried over sodium sulfate and evaporated. Purification of the residue by flash chromatography starting with l5% and finishing with 30% of THF in toluene containing l% of acetic acid afforded the title compound. p.m.r. (CD₃COCD₃, CD₃SOCD₃) δ: 8.28 (d,lH), 8.0 (d,lH), 7.95 (d,lH), 7.55 (dd,lH), 7.45 (d,lH), 7.38 (bs,lH), 7.l5-7.32 (m,3H), 5.23 (s,lH), 3.l-3.3 (m,4H), 2.95 (s,3H), 2.85 (s,3H), 2.4-2.8 p.p.m. (m,8H). EXAMPLE 27 (+)-5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-8-­ DIMETHYLCARBAMYL-4,6-DITHIAOCTANOIC ACID Step l : Preparation of 3-hydroxymethylbenzaldehyde To a solution of isophtalaldehyde (8 g) in ethanol (80 mL) at room temperature was added NaBH₄ portion wise, until about 50% reaction by TLC. The reaction mixture was quenched with 25% ammonium acetate, extracted with ethyl acetate, which was washed with brine (2×), dried over sodium sulfate, filtered and evaporated to dryness. Purification of the residue by flash chromatography using 50% ether in hexane afforded the pure title compound. ¹H NMR (CDCl₃) δ 2.45 (s, lH, OH), 4.78 (s, 2H, C H ₂OH), 7.50-7.90 (m, 4H, Ar), l0.05 (s, lH, CHO). Step 2 : Preparation of 3-t-butyldiphenylsilyloxy­ methylbenzaldehyde To a solution of 3-hydroxymethylbenzaldehyde (step l) (3 g) in methylene chloride (l5 mL) and triethylamine (4.l mL) was slowly added t-butylchlorodiphenyl silane (8 mL). Finally, a few mgs of 4-pyrrolidinopyridine was added as a catalyst. The reaction mixture was stirred overnight at room temperature (R.T.). The solution was quenched with 25% ammonium acetate and extracted with ethyl acetate, which was washed with brine (2×), dried over sodium sulfate, filtered and evaporated to dryness. Purification by flash chromatography, using 4% ethyl acetate in hexane afforded the title compound. ¹H NMR (CDCl₃) δ l.l3 (s, 9H, t-Bu), 4.82 (s, 2H, CH₂O), 7.25-7.85 (m, l4H, Ar), l0.05 (s, lH, CHO). Step 3 : Preparation of (R)-(+)-α-methoxybenzene­ thanethioic acid To (R)-(-)-α-methoxyphenylacetic acid (2 g) in benzene (20 mL) at -l0⁰C was slowly added oxalyl chloride (l.l5 mL) and l drop of DMF. The solution was slowly warmed up to room temperature and stirred for 2 hrs. The solvent was evaporated and the oily residue was coevaporated with toluene (3×). This acid chloride was used as such. I.R. (neat) l790 cm⁻¹ (C=O). To ethanol (20 mL) at -l0⁰C, anhydrous NaSH (l.34g, 2 eq) was added. Then, the acid chloride in THF (8mL) was slowly added. The reaction mixture was stirred for 20 min at -l0⁰C. The mixture was acid­ ified with 6N HCl, extracted with EtOAc, washed with brine (2×), dried Na₂SO₄, filtered and evaporated to dryness to afford (R)-(+)-α-methoxybenzene­ thanethioic acid. [α] +32.7 (C = 3.l, acetone). IR (neat) 2550 (SH) and l700 cm⁻¹ (C=O). Step 4 : Preparation of 3-mercapto-N,N-dimethyl­ propanamide To N,N-dimethylacrylamide (l9.8 g, 0.2 mol) at 0⁰C, was slowly added thioacetic acid (l5.22 g, 0.2 mol). The ice-bath was then removed and the reaction mixture stirred at room temperature for l5 min. On distillation (b.p. 96-98⁰/0.06 Tor) a reddish oil was obtained. To this oil (5.66 g, 32.34 mmol.) in methanol (20 mL) at 0⁰C was added potassium t-butoxide (3.622 g, l eq) in 3 portions. The mixture was stirred at room temperature for l.5 hr. The reaction mixture was poured over 25% ammonium acetate and methylene chloride. 2N HCl was added to bring the pH to 7.0-7.5. After 2 more extractions with methylene chloride, the organic layers were combined, dried over sodium sulfate, filtered, and evaporated to dryness to afford 3-mercapto-N,N-­ dimethylpropanamide as a pale orange oil. Step 5 : Preparation of (-)-methyl 5-(3-(t-butyl­ diphenylsilyloxymethyl)phenyl)-8-dimethyl­ carbamyl-4,6-dithiaoctanoate To a solution of 3-t-butyldiphenylsilyloxy­ methylbenzaldehyde (step 2) (8.98 g, 24 mmol.) in benzene (90 mL) was added 3-mercapto-N,N-­ dimethylpropanamide (step 4) (3.5 g, 26 mmol.), (R)-(+)-α-methoxybenzenethanethioic acid (step 3) (4.76 g, 26 mmol.) and p-toluenesulfonic acid (2.26 g, l3 mmol.). The solution was refluxed for 3.5 hrs with a Dean-Stark apparatus filled with activated 3A molecular sieve. The solution was cooled to room temperature, quenched with 25% ammonium acetate, and extracted with EtOAc, which was washed with brine (3×), dried over sodium sulfate, filtered and evaporated to dryness. The two diastereomers were separated by flash chromatography using 40% of ethyl acetate in hexane. Less polar compound: ¹H NMR (CDCl₃) δ l.l2 (s, 9H, t-Bu), 2.45 (t, 2H, J = 7 Hz, CH₂), 2.78 (t, 2H, J = 7 Hz, CH₂), 2.82 and 2.88 (2s, 6H, N(CH₃)₂), 3.42 (s, 3H, OCH₃), 4.70 (s, lH, CH), 4.74 (s, 2H, CH₂O), 5.6l (s, lH, CH), 7.26 - 7.7l (m, l9H, Ar). More polar compound: ¹H NMR (CDCl₃) δ l.l0 (s, 9H, t-Bu), 3.59 (t, 2H, J = 7 Hz, CH₂), 3.85 (t, 2H, J = 7 Hz, CH₂), 3.95 and 3.96 (2s, 6H, N(CH₃)₂), 3.48 (s, 3H, OCH₃), 4.72 (s, 2H, CH₂O), 4.78 (s, lH, CH), 5.64 (s, lH, CH), 7.26 - 7.85 (m, l9H, Ar). A solution of the less polar compound (2.6 g, 3.87 mmol.) in THF (40 mL) was cooled to -78⁰C. A solution of sodium methoxide (lM) in methanol (3.47 mL, 0.9 eq) was added. After stirring for l0 min (-78⁰C), methyl acrylate (0.52 mL, l.5 eq) was added and the solution was stirred for 2 hrs at -78⁰C. The reaction mixture was quenched at low temperature with a saturated solution of ammonium chloride, and extracted with EtOAc, which was washed with brine (3×), dried over sodium sulfate, filtered and evaporated to dryness. Purification by flash chromatography using 40% ethyl acetate in hexane afforded the title compound. [α] -l.62 (C = l.22, acetone). ¹H NMR (CDCl₃) δ l.l2 (s, 9H, t-Bu), 2.50 - ­ 2.90 (m, 8H, 4(CH₂)), 2.9l and 2.92 (2d, 6H, N(CH₃)₂), 3.68 (s, lH, OCH₃), 4.77 (s, 2H, CH₂O), 5.00 (s, lH, CH), 7.27-7.72 (m, l4H, Ar). Step 6 : Preparation of (-)-methyl 5-(3-(hydroxy­ methyl)phenyl)-8-dimethylcarbamyl-4,6-­ dithiaoctanoate To a solution of (-)-methyl 5-(3-(t-butyl­ diphenylsilyloxymethyl)phenyl)-8-dimethylcarbamyl-­ 4,6-dithiaoctanoate (step 5) (l.377 g, 2.26 mmol.) in THF (25 mL) at room temperature was slowly added tetra-n-butylammonium fluoride (lM) in THF (2.34 mL). The solution was stirred 2 hrs at room temperature Ethyl acetate was added to the reaction mixture, and the organic layer it was washed with brine (3×), dried over sodium sulfate, filtered and evaporated to dryness. Purification by flash chromatography using 40% acetone in hexane afforded the title compound. [α] -4.2 (C = 2.04, acetone). ¹H NMR (CDCl₃) δ 2.50-2.9l (m, 8H, 4(CH₂)), 2.94 and 2.96 (2s, 6H, N(CH₃)₂), 3.70 (s, 3H, OCH₃), 4.69 (s, 2H, C H ₂OH), 5.05 (s, lH, CH), 7.26-7.49 (m, 4H, Ar). Step 7 : Preparation of (-)-methyl 5-(3-formylphenyl)-­ 8-dimethylcarbamyl-4,6-dithiaoctanoate To a solution of (-)-methyl 5-(3-(hydroxy­ methyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoate (step 6) (679 mg) in ethyl acetate (30 mL) was added activated manganese oxide (l.3 g). The suspension was stirred overnight at room temperature. The suspension was filtered on a pad of silica gel and washed with EtOAc. The solvent was evaporated, affording the title compound. [α] -6.9 (C = l.73 acetone). ¹H NMR (CDCl₃) δ 2.56-2.94 (m, 8H, 4(CH₂)), 2.95 and 2.97 (2s, 6H, N(CH₃)₂), 3.70 (s, 3H, OCH₃), 5.l4 (s, lH, CH), 7.52, 7.80 and 7.98 (t, t and s, 4H, Ar), l0.03 (s, lH, CHO). Step 8 : Preparation of (-)-methyl 5-(3-(2-(7-chloro­ quinolin-2-yl)ethenyl)phenyl)-8-dimethyl­ carbamyl-4,6-dithiaoctanoate To a suspension of 7-chloroquinolin-2-yl-­ methyltriphenylphosphonium bromide (809 mg, l.56 mmol.) (Example 4, Step 2) in THF (l5 mL) at -78⁰C, was added a solution of n-BuLi (l.6 M) in hexane (0.89 mL, l.43 mmol.). The mixture was stirred for 0.5 hrs at -78⁰C. Then, (-)-methyl 5-(3-formyl­ phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoate (step 7) (480 mg, l.3 mmol.) in THF (4 mL) was slowly added. The mixture was stirred for 0.5 hr at -78⁰C and then warmed up to room temperature and stirred for an additional 2 hrs. A solution of 25% ammonium acetate was added, the mixture was extracted with ethyl acetate, and the extracts were washed with brine (3×), dried over sodium sulfate, filtered and evaporated to dryness. Purification by flash chromatography afforded the title compound. [α] -4.2 (C = l.28 acetone). ¹H NMR 2.54 - 2.93 (m, 8H, 4(CH₂)), 2.94 (s, 6H, N(CH₃)₂), 3.70 (s, lH, OCH₃), 5.08 (s, lH, CH), 7.34 - 8.l4 (m, llH, Ar). Step 9 : To a solution of (-)-methyl 5-(3-(2-­ (7-chloro-quinolin-2-yl)ethenyl)phenyl)-8-dimethyl­ carbamyl-4,6-dithiaoctanoate (step 8)(640 mg, l.2l mmol.) in peroxide-free l,2-dimethoxyethane (l5 mL) and water (l.5 mL) was added LiOH (lM, l.8 mL, l.8 mmol.). The solution was stirred for 3 hrs at room temperature Water was added and the mixture was washed with EtOAc. The aqueous layer was acidified with lN HCl, extracted with EtOAc, the extracts were washed with brine (2×), dried over Na₂SO₄, filtered and evaporated to dryness. The oily residue was coevaporated 3 or 4 times with EtOAc and finally was allowed to crystallize in this solvent overnight at 0⁰C. Filtration afforded the title compound. [α] +9.l (C = 0.88, l% NaHCO₃). ¹H NMR 2.70-3.l9 (m, 8H, 4(CH₂)), 3.00 and 3.02 (2s, 6H, N(CH₃)₂), 5.l5 (s, lH, CH), 7.34 - 8.l4 (m, llH, Ar). EXAMPLE 28 (-)-5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-8-­ DIMETHYLCARBAMYL-4,6-DITHIAOCTANOIC ACID Step l : Preparation of (+)-methyl 5-(3-(t-butyl­ diphenylsilyloxymethyl)phenyl)-8-dimethyl­ carbamyl-4,6-dithiaoctanoate To a solution of 3-t-butyldiphenylsilyloxy­ methylbenzaldehyde (Example 27, step 2) (8.98 g, 24 mmol.) in benzene (90 mL) was added 3-mercapto-N,N-­ dimethylpropanamide (Example 27, step 4) (3.5 g, 26 mmol.), (R)-(+)-α-methoxybenzenethanethioic acid (Example 27, Step 3) (4.76 g, 26 mmol.) and p-toluenesulfonic acid (2.26 g, l3 mmol.). The solution was refluxed for 3.5 hrs with a Dean-Stark apparatus filled with activated 3A molecular sieves. The solution was cooled to room temperature, quenched with 25% ammonium acetate, and extracted with EtOAc, which was washed with brine (3×), dried over sodium sulfate, filtered and evaporated to dryness. The two diastereomers were separated by flash chromatography using 40% of ethyl acetate in hexane. Less polar compound: ¹H NMR (CDCl₃) δ l.l2 (s, 9H, t-Bu), 2.45 (t, 2H, J = 7 Hz, CH₂), 2.78 (t, 2H, J = 7 Hz, CH₂), 2.82 and 2.88 (2s, 6H, N(CH₃)₂), 3.42 (s, 3H, OCH₃), 4.70 (s, lH, CH), 4.74 (s, 2H, CH₂O), 5.6l (s, lH, CH), 7.26 - 7.7l (m, l9H, Ar). More polar compound: ¹H NMR (CDCl₃) δ l.l0 (s, 9H, t-Bu), 3.59 (t, 2H, J = 7 Hz, CH₂), 3.85 (t, 2H, J = 7 Hz, CH₂), 3.95 and 3.96 (2s, 6H, N(CH₃)₂), 3.48 (s, 3H, OCH₃), 4.72 (s, 2H, CH₂O), 4.78 (s, lH, CH), 5.64 (s, lH, CH), 7.26 - 7.85 (m, l9H, Ar). A solution of the more polar compound (2.6 g, 3.87 mmol.) in THF (40 mL) was cooled to -78⁰C. A solution of sodium methoxide lM in methanol (3.47 mL, 0.9 eq) was added. After stirring for l0 min (-78⁰C), methyl acrylate (0.52 mL, l.5 eq) was added and the solution was stirred for 2 hrs at -78⁰C. The reaction mixture was quenched at low temperature with a saturated solution of ammonium chloride, and extracted with EtOAc, which was washed with brine (3×), dried over sodium sulfate, filtered and evaporated to dryness. Purification by flash chromatography using 40% ethyl acetate in hexane afforded the title compound. [α] +2.05 (C = l.84, acetone). ¹H NMR (CDCl₃) δ l.l2 (s, 9H, t-Bu), 2.50 - ­ 2.90 (m, 8H, 4(CH₂)), 2.9l and 2.92 (2d, 6H, N(CH₃)₂), 3.68 (s, lH, OCH₃), 4.77 (s, 2H, CH₂O), 5.00 (s, lH, CH), 7.27-7.72 (m, l4H, Ar). Step 2 : Preparation of (+)-methyl 5-(3-(hydroxy­ methyl)phenyl)-8-dimethylcarbamyl-4,6-dithi­ aoctanoate To a solution of (+)-methyl 5-(3-(t-butyl­ diphenylsilyloxymethyl)phenyl)-8-dimethylcarbambyl-4,6-­ dithiaoctanoate (step l) (l.377 g, 2.26 mmol.) in THF (25 mL) at room temperature was slowly added tetra-n-­ butylammonium fluoride lM in THF (2.34 mL). The solution was stirred 2 hrs at room temperature Ethyl acetate was added to the reaction mixture, it was washed with brine (3×), dried over sodium sulfate, filtered and evaporated to dryness. Purification by flash chromatography using 40% acetone in hexane afforded the title compound. ¹H NMR (CDCl₃) δ 2.50-2.9l (m, 8H, 4(CH₂)), 2.94 and 2.96 (2s, 6H, N(CH₃)₂), 3.70 (s, 3H, OCH₃), 4.69 (s, 2H, C H ₂OH), 5.05 (s, lH, CH), 7.26-7.49 (m, 4H, Ar). Step 3 : Preparation of (+)-methyl 5-(3-formylphenyl)-­ 8-dimethylcarbamyl-4,6-dithiaoctanoate To a solution of (+)-methyl 5-(3-(hydroxy­ methyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoate (step 2) (679 mg) in ethyl acetate (30 mL) was added activated manganese oxide (l.3 g). The suspension was stirred overnight at room temperature. The suspension was filtered on a pad of silica gel and washed with EtOAc. The solvent was evaporated, affording the title compound. [α] +6.7 (C = l.38, acetone). ¹H NMR (CDCl₃) δ 2.56-2.94 (m, 8H, 4(CH₂)), 2.95 and 2.97 (2s, 6H, N(CH₃)₂), 3.70 (s, 3H, OCH₃), 5.l4 (s, lH, CH), 7.52, 7.80 and 7.98 (t, t and s, 4H, Ar), l0.03 (s, lH, CHO). Step 4 : Preparation of (+)-methyl 5-(3-(2-(7-chloro­ quinolin-2-yl)ethenyl)phenyl)-8-dimethyl­ carbamyl-4,6-dithiaoctanoate To a suspension of 7-chloroquinolin-2-yl­ methyltriphenylphosphonium bromide (Example 4, Step 2) (809 mg, l.56 mmol.) in THF (l5 mL) at -78⁰C, was added a solution of n-BuLi (l.6 M) in hexane (0.89 mL, l.43 mmol.). The mixture was stirred for 0.5 hrs at -78⁰C. Then, (+)-methyl 5-(3-formylphenyl)-8-­ dimethylcarbamyl-4,6-dithiaoctanoate (step 3) (480 mg, l.3 mmol.) in THF (4 mL) was slowly added. The mixture was stirred for 0.5 hr at -78⁰C and then warmed up to room temperature and stirred for an additional 2 hrs. A solution of 25% ammonium acetate was added, the mixture was extracted with ethyl acetate, and the extracts were washed with brine (3×), dried over sodium sulfate, filtered and evaporated to dryness. Purification by flash chromatography afforded the title compound. [α] +3.5 (C = l.74, acetone). ¹H NMR 2.54 - 2.93 (m, 8H, 4(CH₂)), 2.94 (s, 6H, N(CH₃)₂), 3.70 (s, lH, OCH₃), 5.08 (s, lH, CH), 7.34 - 8.l4 (m, llH, Ar). Step 5 : To a solution of (+)-methyl 5-(3-(2-­ (7-chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethyl­ carbamyl-4,6-dithiaoctanoate (step 4) (640 mg, l.2l mmol.) in peroxide free l,2-dimethoxyethane (l5 mL) and water (l.5 mL) was added LiOH (lM, l.8 mL, l.8 mmol.). The solution was stirred for 3 hrs at room temperature Water was added and the mixture was washed with EtOAc. The aqueous layer was acidified with lN HCl, extracted with EtOAc, the extracts were washed with brine (2×), dried over Na₂SO₄, filtered and evaporated to dryness. The oily residue was coevaporated 3 or 4 times with EtOAc and finally was allowed to crystallize in this solvent overnight at 0⁰C. Filtration afforded the title compound. [α] -9.2 (C = 0.68, l% NaHCO₃). ¹H NMR 2.70-3.l9 (m, 8H, 4(CH₂)), 3.00 and 3.02 (2s, 6H, N(CH₃)₂), 5.l5 (s, lH, CH), 7.34 - 8.l4 (m, llH, Ar). EXAMPLE 29 5-(3-(2-(7-CHLOROQUINOLIN-2-YL)ETHENYL)PHENYL)-3-7-­ DIMETHYL-4,6-DITHIANONANEDIOIC ACID Using the procedure of Example l by substituting methyl 3-mercaptobutanoate for methyl 3-mercaptopropanoate in Step l there was obtained the title compound. p.m.r. ((CD₃)₂CO) δ: l.3 (m,6H), 2.3 to 2.8 (m,4H), 3.2 to 3.4 (m,2H), 5.45 (t,lH), 7.4 to 7.6 (m,4H), 7.7 (bd,lH), 7.85 to 8.0 (m,4H) 8.05 (d,lH), 8.35 p.p.m. (d,lH). EXAMPLE 30 5-(3-(7-CHLOROQUINOLIN-2-YLMETHOXY)PHENYL)-3,3,7,7-­ TETRAMETHYL-4,6-DITHIANONANEDIOIC ACID Using the procedure of Example l6 (Step 2) by substituting 3-methyl-3-mercaptobutanoic acid for 3-mercaptopropanoic acid in Step 3 there was obtained the title compound. p.m.r. ((CD₃)₂SO) δ: l.05 (s,6H), l.2 (s,6H), 2.4 (q,4H), 5.l5 (s,2H), 5.30 (s,3H), 6.7 (dd,lH), 6.9 (d,lH), 7.0 (m,lH), 7.35 (dd,lH), 7.5 (d,lH), 7.65 (m,2H), 7.85 (d,lH), 8.l p.p.m. (d,lH). Using the methods described in the preceding examples, the following compounds are prepared. EXAMPLE 3l 5-(3-(2-(7-TRIFLUOROMETHYLQUINOLIN-2-YL)ETHENYL)­ PHENYL)-8-N-DIMETHYLCARBAMYL-4,6-DITHIAOCTANOIC ACID EXAMPLE 32 8-N-t-BUTYLCARBAMYL-5-(3-(6-(METHANESULFONYL)QUINOLIN-­ 2-YLMETHOXY)PHENYL)-4,6-DITHIAOCTANOIC ACID EXAMPLE 33 5-(3-(7-FLUOROQUINOLIN-2-YL-METHYLTHIO)PHENYL)-4,6-­ DITHIANONANEDIOIC ACID EXAMPLE 34 8-CARBAMYL-5-(3-(2-(6-CYANOQUINOLIN-2-YL)ETHENYL)­ PHENYL)-4,6-DITHIAOCTANAMIDE EXAMPLE 35 8-(N-METHANESULFONYL)CARBAMYL)-5-(3-(2-(7-CHLORO­ QUINOLIN-2-YL)ETHENYL)PHENYL)-4,6-DITHIAOCTANOIC ACID EXAMPLE 36 9-HYDROXY-5-(3-(6,7-DIFLUOROQUINOLIN-2-YLMETHOXY)­ PHENYL)-4,6-DITHIANONANOIC ACID EXAMPLE 37 9-HYDROXY-5-(3-(2-(7-(TRIFLUOROMETHYLTHIO)QUINOLIN-2-­ YL)ETHENYL)PHENYL)-4,6-DITHIANONANOIC ACID EXAMPLE 38 8-FORMYL-5-(3-((7-TRIFLUOROMETHANESULFONYL)QUINOLIN-2-­ YLMETHYLTHIO)PHENYL)-4,6-DITHIAOCTANOIC ACID EXAMPLE 39 4-(3-(7-CHLOROQUINOLIN-2-YLMETHOXY)PHENYL)-3,5-DITHIA­ HEPTANEDIOIC ACID m.p. l57-l58⁰ Anal. Calc. C₂₁H₁₈ClNO₅S₂ requires: C 54.36, H 3.9l, Cl 7.64, N 3.02, S l3.82; found: C 54.70, H 3.96, Cl 7.68, N 3.0l, S l4.03. EXAMPLE 40 SODIUM 6-DIMETHYLCARBAMYL-4-(3-(7-CHLOROQUINOLIN-2-YL­ METHOXY)PHENYL)-3,5-DITHIAHEXANOATE MONOHYDRATE Anal. Calc. C₂₃H₂₂ClN₂NaO₄S₂·H₂O requires: C 52.02, H 4.56, Cl 6.68, N 5.27, S l2.08; found: C 5l.66, H 4.67, Cl 6.87, N 5.07, S l2.05. EXAMPLE 4l 6-CARBAMYL-4-(3-(7-CHLOROQUINOLIN-2-YLMETHOXY)PHENYL)-­ 3,5-DITHIAHEXANOIC ACID m.p. l73⁰C after sintering at approx. l45⁰C. Anal. Calc. C₂₁H₁₉ClN₂O₄S requires: C 54.48, H 4.l4, N 6.05; found: C 54.44, H 4.27, N 5.97. EXAMPLE 42 5-(3-(7-FLUOROQUINOLIN-2-YLMETHOXY)PHENYL)-4,6-DITHIA­ NONANEDIOIC ACID m.p. l39-l40⁰C. Anal. Calc. C₂₃H₂₂FNO₅S₂ requires: C 58.09, H 4.66, N 2.95, S l3.48; found: C 58.08, H 4.82, N 3.07, S l3.48. EXAMPLE 43 8-DIMETHYLCARBAMYL-5-(3-(7-FLUOROQUINOLIN-2-YL­ METHOXY)PHENYL)-4,6-DITHIAOCTANOIC ACID m.p. l52-l53⁰C. Anal. Calc. C₂₅H₂₇FN₂O₄S₂ requires: C 59.74, H 5.4l, N 5.57, S l2.76; found: C 59.95, H 5.6l, N 5.56, S l2.84. EXAMPLE 44 5-(3-(7-TRIFLUOROMETHYLQUINOLIN-2-YLMETHOXY)PHENYL)-­ 4,6-DITHIANONANEDIOIC ACID m.p. l56-l57⁰C. Anal. Calc. C₂₄H₂₂F₃NO₅S₂ requires: C 54.85, H 4.22, N 2.66, S l2.20; found: C 55.05, H 4.29, N 2.70, S l2.40. EXAMPLE 45 8-DIMETHYLCARBAMYL-5-(3-(7-TRIFLUOROMETHYLQUINOLIN-2-­ YLMETHOXY)PHENYL)-4,6-DITHIAOCTANOIC ACID m.p. l30-l3l⁰C. Anal. Calc. C₂₆H₂₇F₃N₂O₄S₂ requires: C 56.5l, H 4.92, N 5.07, S ll.60; found: C 56.50, H 5.08, N 4.94, S ll.73. EXAMPLE 46 8-DIMETHYLCARBAMYL-5-(3-(2-(7-METHYLQUINOLIN-2-YL)­ ETHENYL)PHENYL)-4,6-DITHIAOCTANOIC ACID

Claims: 1. A compound of the formula: wherein: R¹ is H, halogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, -CF₃, -OR², -SR², -S(O)R², -S(O)₂R², -NR²R², -CHO, -COOR², -(C=O)R², -C(OH)R²R², -CN, -NO₂, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, or substituted or unsubstituted phenethyl; R² is H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, -CF₃, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, or substituted or unsubstituted phenethyl; R³ is H, halogen, -NO₂, -CN, -OR², -SR², NR²R², or C₁-C₈ alkyl; CR²R³ may be the radical of a naturally occurring amino acid; R⁴ is H, halogen, -NO₂, -CN, -OR², -SR², NR²R², C₁-C₈ alkyl, or -(C=O)R²; R⁶ is H or C₁-C₄ alkyl; R⁷ is A) a monocyclic or bicyclic heterocyclic radical containing from 3 to l2 nuclear carbon atoms and l or 2 nuclear hetero­ atoms selected from N, S or O and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or B) the radical W-R⁸; R⁸ contains up to 2l carbon atoms and is (l) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more that l heteroatom in the ring; R⁹ is -OR¹⁰, -SR¹⁰, or NR¹⁰R¹⁰; R¹⁰ is H, C₁-C₆ alkyl, -(C=O)R¹¹, unsubstituted phenyl, unsubstituted benzyl, or two R¹⁰ groups joined to the same N may form a ring of 5 or 6 members containing up to two heteratoms chosen from O, S or N; R¹¹ is H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, -CF₃, or unsubstituted phenyl, benzyl, or phenethyl; R¹² is R² or halogen; m and m′ are independently 0-8; n and n′ are independently 0 or l; p and p′ are independently 0-8; m + n + p is l-l0; m′ + n′ + p′ is l-l0; s is 0-3; Q¹ and Q² are independently -COOR², tetrazole, -COOR⁵, -CONHS(O)₂R¹¹, -CN, -CONR¹⁰R¹⁰, -CHO, -CH₂OH, -COCH₂OH, -NHS(O)₂R¹¹; or if Q¹ or Q² is COOH and R₃ is -OH, -SH, or -NHR² then Q¹ or Q² and R³ and the carbons through which they are attached may form a heterocyclic ring with loss of water; W is O, S, or NH; X¹ is O, S, -S(O)-, -S(O)₂-, -NR², or -CR²R²-; X² and X³ are independently O, S, S(O), or S(O)₂; Z¹ and Z² are independently -CONR²-; and the pharmaceutically acceptable salts thereof. 2. A compound of Claim l of the Formula Ia: wherein: Y is -CR²=CR²-, -CC-, CRO, or -CRS-; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. 3. A compound of Claim l of the Formula Ib: wherein: R¹ is H, halogen, C₁-C₃ alkyl, -CF₃, or SCF₃; R² is H, C₁-C₃ alkyl, C₂-C₃ alkenyl, or -CF₃; X² and X³ are independently O or S; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. 4. A compound of Claim l of the Formula Ic: wherein: R¹ is H, halogen, C₁-C₃ alkyl, -CF₃, or SCF₃; R² is H, C₁-C₃ alkyl, C₂-C₃ alkenyl, or -CF₃; X² and X³ are independently O or S; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. 5. A compound of Claim l of the Formula Id: wherein: R¹ is H, halogen, C₁-C₃ alkyl, -CF₃, or SCF₃; R² is H, C₁-C₃ alkyl, C₂-C₃ alkenyl, or CF₃; X² and X³ are independently O or S; Y is -CRO- or -CRS-; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. 6. A compound of Claim l of Formula Ie which is: 7. A compound of Claim 6 which is 4, 6, l3, l6, 27, or 28. 8. A pharmaceutical composition useful in antagonizing leukotriene action in mammals comprising an amount of a compound of Claim l effective as a leukotriene antagonist and a pharmaceutically acceptable carrier. 9. The pharmaceutical composition of Claim 8 additionally comprising an effective amount of a second active ingredient selected from the group consisting of non-steroidal anti-inflammatory drugs; peripheral analgesic agents; cyclooxygenase inhibitors; leukotriene antagonists; leukotriene inhibitors; H₂-receptor antagonists; antihistaminic agents; prostaglandin antagonists; thromboxane antagonists; and serotonin antagonists. l0. The use of a compound as claimed in Claim l for the manufacture of a medicament useful for preventing the synthesis, the action, or the release of SRS-A or leukotriene D₄ in mammals. Claims for the following Contracting States :AT, ES, GR 1. A process for the preparation of a compound of formula: wherein: R¹ is H, halogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, -CF₃, -OR², -SR², -S(O)R², -S(O)₂R², -NR²R², -CHO, -COOR², -(C=O)R², -C(OH)R²R², -CN, -NO₂, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, or substituted or unsubstituted phenethyl; R² is H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, -CF₃, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, or substituted or unsubstituted phenethyl; R³ is H, halogen, -NO₂, -CN, -OR², -SR², NR²R², or C₁-C₈ alkyl; CR²R³ may be the radical of a naturally occurring amino acid; R⁴ is H, halogen, -NO₂, -CN, -OR², -SR², NR²R², C₁-C₈ alkyl or -(C=O)R²; R⁶ is H or C₁-C₄ alkyl; R⁷ is A) a monocyclic or bicyclic heterocyclic radical containing from 3 to l2 nuclear carbon atoms and l or 2 nuclear hetero­ atoms selected from N, S or O and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or B) the radical W-R⁸; R⁸ contains up to 2l carbon atoms and is (l) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more that l heteroatom in the ring; R⁹ is -OR¹⁰, -SR¹⁰, or NR¹⁰R¹⁰; R¹⁰ is H, C₁-C₆ alkyl, -(C=O)R¹¹, unsubstituted phenyl, unsubstituted benzyl, or two R¹⁰ groups joined to the same N may form a ring of 5 or 6 members containing up to two heteratoms chosen from O, S or N; R¹¹ is H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, -CF₃, or unsubstituted phenyl, benzyl, or phenethyl; R¹² is R² or halogen; m and m′ are independently 0-8; n and n′ are independently 0 or l; p and p′ are independently 0-8; m + n + p is l-l0; m′ + n′ + p′ is l-l0; s is 0-3; Q¹ and Q² are independently -COOR², tetrazole, -COOR⁵, -CONHS(O)₂R¹¹, -CN, -CONR¹⁰R¹⁰, -CHO, -CH₂OH, -COCH₂OH, -NHS(O)₂R¹¹; or if Q¹ or Q² is COOH and R³ is -OH, -SH, or -NHR² then Q¹ or Q² and R³ and the carbons through which they are attached may form a heterocyclic ring with loss of water; W is O, S, or NH; X¹ is O, S, -S(O)-, -S(O)₂-, -NR², or -CR²R²-; X² and X³ are independently O, S, S(O), or S(O)₂; Z¹ and Z² are independently -CONR²-; and the pharmaceutically acceptable salts thereof which process comprises: A) reacting a styryl quinoline derivative of formula V: with a compound of formula HX²-(CR²₂)m-Z¹n-(CR²R³)p-Q¹ and HX³-(CR²₂)m′-Z²n′-(CR²R³)p′-Q²; B) condensing a compound of formula (VIII): with a quinoline derivative of formula (X): where Z is H or Ph₃P⁺, in the presence of either a dehydrating agent (if Z = H), or a base (if Z = Ph₃P⁺); or C) reacting an acetal derviative of formula (IX): with a compound of formula (X): where Z is leaving group; and optionally after step (A), (B) or (C), converting one group Y to different group Y. 2. A process as claimed in Claim l for the preparation of a compound of the Formula Ia: wherein: Y is -CR²=CR²-, -CC-, CRO, or -CRS-; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. 3. A process as claimed in Claim l for the preparation of a compound of the Formula Ib: wherein: R¹ is H, halogen, C₁-C₃ alkyl, -CF₃, or SCF₃; R² is H, C₁-C₃ alkyl, C₂-C₃ alkenyl, or -CF₃; X² and X³ are independently O or S; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. 4. A process as claimed in Claim l for the preparation of a compound of the Formula Ic: wherein: R¹ is H, halogen, C₁-C₃ alkyl, -CF₃, or SCF₃; R² is H, C₁-C₃ alkyl, C₂-C₃ alkenyl, or -CF₃; X² and X³ are independently O or S; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. 5. A process as claimed in Claim l for the preparation of a compound of the Formula Id: wherein: R¹ is H, halogen, C₁-C₃ alkyl, CF₃, or SCF₃; R² is H, C₁-C₃ alkyl, C₂-C₃ alkenyl, or CF₃; X² and X³ are independently O or S; Y is -CRO- or -CRS-; the other substituents are as defined for Formula I; and the pharmaceutically acceptable salts thereof. 6. A process as claimed in Claim l for the preparation of a compound of the Formula Ie which is: 7. A process as claimed in Claim 6 for the preparation of a compound which is 4, 6, l3, l6, 27, or 28. 8. A process for preparing a pharmaceutical composition useful in antagonizing leukotriene action in mammals comprising mixing an amount of a compound of Claim l effective as a leukotriene antagonist and a pharmaceutically acceptable carrier. 9. A process as claimed in Claim 8 comprising additionally mixing an effective amount of a second active ingredient selected from the group consisting of non-steroidal anti-inflammatory drugs; peripheral analgesic agents; cyclooxygenase inhibitors; leukotriene antagonists; leukotriene inhibitors; H₂-receptor antagonists; antihistaminic agents; prostaglandin antagonists; thromboxane antagonists; and serotonin antagonists.

Inventors: LEGER, SERGE, YOUNG, ROBERT N., ZAMBONI, ROBERT
Applicants: MERCK FROSST CANADA INC.
Application year: 1987
Main classification: C07D215
IPC codes: A61K31, C07D401, C07D215, A61P37, A61P11, A61P43, A61P29